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ABSTRACT 
 
 The widespread use of soy protein-based infant formulas for human infant 
nutrition has raised concerns regarding potential estrogenic effects of soy isoflavones on 
normal development and adult function of the reproductive system in humans and 
animals.  The isoflavone genistein is the most estrogenically active molecule present in 
soy.  Human infants may also be exposed to other environmental estrogens.  Bottle fed 
infants are most likely exposed to bisphenol A.  The xenoestrogen bisphenol A (BPA) 
has a chemical structure similar to the potent synthetic estrogen diethylstilbestrol (DES), 
and is found in plastic baby bottles.  This study tested the hypothesis that neonatal 
genistein and/or BPA exposure cause male reproductive tract defects.  Male C57Bl/6 
mice were orally treated from postnatal day 1 (PND 1) to PND 5 with a dose of genistein 
(50 mg/kg) that resulted in physiological genistein serum levels or a dose of BPA equal 
to the no observable adverse effect level (50mg/kg) for reproductive toxicity or a 
combination of genistein and BPA at three different concentrations of BPA (50mg/kg 
genistein; 0.5, 5, or 50 mg/kg of BPA; Gen/BPA0.5, Gen/BPA5, and Gen/BPA50 
respectively).  DES injected at 1ng/g was used as a positive control for assessment of 
changes in male reproductive tract development.  The endpoints chosen for the study 
were germ cell proliferation, efferent duct epithelial cell height, anogenital distance, daily 
sperm production, testis weight, and reproductive performance.  Treatment with 50 
mg/kg genistein did not alter any of the endpoints measured.  Germ cell proliferation was 
increased with BPA, Gen/BPA0.5, Gen/BPA5, and Gen/BPA50 treatment.  Treatment 
with BPA also resulted in an increase in daily sperm production at both postnatal day 35 
and 110   The phenomenon of increased daily sperm production was also seen with the 
combination of genistein and BPA at two of the three treatment doses (Gen/BPA0.5 and 
Gen/BPA50).  An increase in daily sperm production may be due to an increase in germ 
cell proliferation that was observed at postnatal day five with BPA, Gen/BPA0.5, or 
Gen/BPA50 treatment.  Animals treated with BPA and the combination of genistein and 
BPA did not have a significant increase in testis weights as a result of the increase in 
daily sperm production.  Treatment with three different doses of BPA in combination 
with genistein resulted in a nonmonotonic dose response curve.  Presence of a 
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nonmonotonic dose response curve indicates that doses of BPA below the NOAEL may 
cause effects and should be further investigated.  The results of the current study indicate 
that environmental estrogens, such as the soy phytoestrogen genistein at physiological 
concentrations, did not cause adverse affects on the developing or adult male 
reproductive tract.  In contrast, BPA is capable of increasing germ cell proliferation 
during development and increasing juvenile and adult daily sperm production.  The 
combination of genistein and BPA also was capable of increasing germ cell proliferation 
and increasing daily sperm production.  These results show that BPA is capable of 
eliciting a response at a dose below the reported NOAEL when combined with other 
environmental estrogens.  Although the effects seen here may not be considered adverse, 
the ability of a chemical to alter reproductive system development is noteworthy and 
warrants further investigation.
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CHAPTER 1: REVIEW OF LITERATURE 
1.1. ESTROGEN RECEPTOR 
 
1.1.A. Sources of Estrogen in the Male Reproductive Tract 
Once thought to be primarily a female hormone contributing to female health and 
fertility, estrogen is produced by males and plays an essential function in male fertility as 
well (Korach et al. 1996; Hess et al. 1997; Luconi et al. 2002).  There is a high 
concentration of estrogen in the rete testis fluid of the rat (Free and Jaffe 1979) and 
concentrations of estrogen in the testis, rete testis fluid, and testicular venous blood far 
exceed the concentration in male serum in various species, indicating a testicular site of 
estrogen synthesis (Hess 2000, 2003).    
Estrogen biosynthesis is catalyzed by a microsomal member of the cytochrome 
P450 superfamily, aromatase cytochrome P450 (Simpson et al. 1994).  Aromatase 
expression was first described in germ cells of the adult mouse testis (Nitta et al. 1993).  
However, aromatase is expressed in the testis at all stages of development (O'Donnell et 
al. 2001), and estrogen production has been reported in fetal testis (Weniger et al. 1993).  
Leydig and Sertoli cells both contribute to estrogen production in the immature postnatal 
(Tsai-Morris et al. 1985; Dorrington and Khan 1993) and adult testis (Carreau et al. 
1999).  Immature Sertoli cells show high levels of basal and FSH–stimulated aromatase 
activity, which declines as the Sertoli cells cease division and commence maturation into 
terminally differentiated cells (Dorrington and Khan 1993; O'Donnell et al. 2001).  
Unlike Sertoli cells, which decrease estrogen production during maturation, Leydig cells 
increase estrogen production as they mature (Tsai-Morris et al. 1985; Papadopoulos et al. 
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1986).  Leydig cell aromatase is regulated by LH and T in adult cells (Genissel et al. 
2001).  Aromatase knockout mice are initially fertile but develop progressive infertility.  
Aromatase knockout mice develop impaired spermatogenesis between 4.5 and 12 months  
of age, with no alteration in gonadotropins and androgens (Robertson et al. 1999).  
Aromatase knockout mice show an arrest at early spermatogenic stages, indicating that 
local expression of aromatase is essential for spermatogenesis, and provides evidence for 
a direct action of estrogen on male germ cell development and thus fertility (Robertson et 
al. 1999).  Aromatase is first detectable in pachytene spermatocytes and remains in germ 
cells throughout spermiogenesis, becoming restricted to the elongated spermatid 
cytoplasm and flagella (Nitta et al. 1993; Janulis et al. 1996; Janulis et al. 1996; Janulis et 
al. 1998).  P450 aromatase has been identified in rat sperm cytoplasmic droplets (Janulis 
et al. 1996; Hess 2000), and human sperm flagella (Aquila et al. 2002).  Localization of 
aromatase to sperm indicates that sperm may provide a local source of estrogens in the 
epididymis and in the female reproductive tract.  Growth factors and cytokines have been 
reported to influence germ cell aromatase expression, which is also stimulated by cAMP 
(Bourguiba et al. 2003).  The production of estrogen by the germ cells and secretion into 
the seminiferous tubule fluid may be important for the function of the efferent ductules 
and epididymis (Hess 2000, 2003).   
 Although estrogen biosynthesis by the testis is necessary for proper 
spermatogenesis to occur, inappropriate exposure to estrogen can be deleterious to testis 
development.  Exposure to estrogen during the fetal and neonatal period can impact the 
development and organization of the hypothalamic-pituitary-testis (HPT) axis (Cook et 
al. 1998; Atanassova et al. 1999; O'Donnell et al. 2001).  Neonatal exposure to even 
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weakly estrogenic substances can elevate FSH levels during puberty in rats and cause 
long-term changes in the testis (Atanassova et al. 2000).  Exogenous estrogen exposure 
has been shown to inhibit proliferation of precursor Leydig cells during the neonatal 
period, thus altering steroidogenic capacity of adult testis (Abney 1999; O'Donnell et al. 
2001).  Neonatal exposure to diethylstilbestrol (DES) impairs testicular steroidogenesis in 
adulthood via a mechanism which cannot be explained by affects on the HPT axis 
(Atanassova et al. 1999).  Exposure to DES during the neonatal Sertoli cell proliferative 
period decreases Sertoli cell number (Sharpe et al. 1998).  The affect of DES is thought to 
be through a reduction of FSH, which is a mitogen for Sertoli cell proliferation.  Fetal 
exposure to estrogen does not appear to affect Sertoli cell proliferation in the rat (Cook et 
al. 1998; Wistuba et al. 2003).  Estrogen may also inhibit Sertoli cell maturation, 
preventing premature Sertoli cell differentiation during the proliferative period.  Neonatal 
estrogen administration causes a maturational delay in Sertoli cells in rats (Sharpe et al. 
1998).  In the early postnatal period proliferation of rat gonocytes, which express ER 
(Saunders et al. 1998), is stimulated by estradiol in vitro (Li et al. 1997).  It has also been 
shown that exposure to xeno- or phytoestrogens in utero up-regulates the expression of 
platelet-derived growth factor (PDGF) receptors in gonocytes (Thuillier et al. 2003).  
PDGF is known to stimulate gonocytes proliferation in vitro (Li et al. 1997).  Other 
studies using strong estrogens such as DES and estradiol show inhibition of gonocytes 
numbers in cultured fetal rat testes (Lassurguere et al. 2003).  These results indicate that 
estrogen can have both inhibitory and stimulatory affects on gonocyte proliferation. 
 In the adult, maintenance of spermatogenesis is dependent on normal levels of 
FSH, LH and T, and it is important to consider that estrogen is a component of the 
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negative feedback action on gonadotropin secretion at the level of the hypothalamus and 
pituitary.  Therefore high doses of estrogen administered to adult rats are expected to 
decrease serum FSH, LH and T.  However, low doses of estrogen are capable of 
stimulating FSH (Jong et al. 1975). 
 
1.1.B. Expression of Estrogen Receptors in the Male Tract 
The actions of estrogen are mediated through estrogen receptors.  ER and ER 
are encoded by two different genes located on different chromosomes.  Multiple RNA 
splice variants for ER (Flouriot et al. 1998) and alternative splice variants (Gaskell et al. 
2003; Aschim et al. 2004; Zhou et al. 2006) and polymorphisms (Aschim et al. 2005) for 
ER have been reported for humans.  Such a molecular diversity due to alternative 
splicing mechanisms of the correspondent genes is also observed in rodents (Kuiper and 
Gustafsson 1997; Petersen et al. 1998; Varayoud et al. 2005).  Estrogen receptors are 
members of the steroid receptor superfamily of ligand-activated transcription factors 
(Evans 1988).  Estrogen receptors reside within the nucleus of target cells in an inactive 
state in the absence of ligand.  Upon binding its ligand, 17-estradiol (E2), the receptor 
undergoes an activating conformational change permitting it to interact with specific 
cofactors and bind DNA response elements within target gene promoters (Beekman et al. 
1993; Horwitz et al. 1996).  The DNA-bound receptor-ligand complex is then capable of 
either activating or repressing target gene transcription, depending on both the cell and 
the promoter context.  Estrogen receptors are known to play crucial roles in control of 
reproduction and reproductive behavior and development of secondary sexual 
characteristics in animals (Evans 1988).  However, estrogen receptors are quite 
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promiscuous in ligand binding (Anstead et al. 1997; Blair et al. 2000), and many non-
steroidal compounds in the environment have been found to possess estrogenic activity 
(Sohoni and Sumpter 1998; Akingbemi and Hardy 2001) as a result of binding to ER 
and ER.   
The estrogen receptor knockout mouse models have illustrated the importance of 
estrogen in the male reproductive tract.  The creation of these models shed light on the 
idea that estrogen was not only a female hormone.  The reproductive tract of males 
homozygous for estrogen receptor alpha disruption (ERKO) develops normally during 
the prenatal period.  However, ERKO males display atrophy of the testes and 
seminiferous tubules, tubule dysmorphogenesis, and reduced sperm counts as they age 
(Lubahn et al. 1993; Eddy et al. 1996; Rissman et al. 1999).  These males also appear to 
be infertile (Lubahn et al. 1993).  However, ERKO mice are infertile primarily due to 
the malfunctioning of the efferent ductules of the epididymis (Hess et al. 1997).   
Estrogen also functions through a second ER isoform, ERER is expressed at 
high levels in estrogen-target tissues such as prostate (Weihua et al. 2001) and testis 
(Makinen et al. 2001).  Although ER mice are infertile, ER knockout mice are fertile 
(Krege et al. 1998).  These males exhibit normal fertility and sperm counts (Couse et al. 
1999).  The drastic difference in phenotype between the two ER knockout animals 
illustrates the different roles these two receptors play.  It is known that ER levels may 
determine the cellular response to ER ligands (Meegan and Lloyd 2003).  ER stability is 
also influenced by specific ligands (Wijayaratne and McDonnell 2001), which may cause 
the interaction of the receptor with tissue-specific coregulators (Nilsson et al. 2001) and 
ER–associated proteins (Saceda et al. 1998) or with the proteasome degradation pathway 
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(Marsaud et al. 2003).  Estrogen’s function varies depending on the isoform that is 
activated.  For example, in breast cancer cell lines, E2 in the presence of ER elicits 
proliferation, but in the presence of ER, it inhibits proliferation (Strom et al. 2004).   In 
vitro studies show that homo- and heterodimers of ERand ER can form (Cowley et al. 
1997; Pettersson et al. 1997), and it has been proposed that in cells expressing both 
ERand ER, ER may act to modulate ER transcriptional activity and that the relative 
expression of both subtypes is central to determining cellular responses to estrogenic 
ligands (Hall and McDonnell 1999).   
Knockout animals lacking both ER and  (ERKO) were also generated to 
clarify the roles of each receptor in the physiology of estrogen target tissues.  ERKO 
males possess a grossly normal reproductive tract.  However, they are infertile (Couse et 
al. 1999).  The testis of adult (2.5 to 7 months) ERKO males exhibited various stages 
of spermatogenesis.  However, the number of epididymal sperm was reduced by 
approximately 80%, and the motility was reduced to 5% (Couse et al. 1999).    The 
phenotype of ER males is similar to that of ERKO males.   
 Both ER and ER are present in fetal rodent testis (Cooke, et al. 1991; Fisher et 
al. 1997; Saunders et al. 1997; Saunders et al. 1998; van Pelt et al. 1999; Akingbemi 
2005). Although ER has only been localized to the fetal Leydig cell (Fisher et al. 1997; 
Jefferson et al. 2000),  ER has been localized to the Sertoli cell, Leydig cell, and 
gonocytes in rodents (Saunders et al. 1997; 1998; van Pelt et al. 1999) and humans 
(Gaskell et al. 2003).  Studies have shown that ER occurs in two isoforms within the 
human testis, wild-type ER also known as ER1 and ER2 a splice variant which may 
also act as a dominant negative receptor.  Human fetal gonocytes contain mRNA for both 
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splice variants, but only ER2 protein is present in relatively high levels in these cells.  
Expression of the ER2 isoform in gonocytes suggests there may be limited estrogen 
action (Gaskell et al. 2003).  In contrast, human fetal Sertoli cells, Leydig cells, and 
peritubular cells appeared to contain both ER isoforms, suggesting that these cells are 
capable of responding to estrogens (Gaskell et al. 2003).   
In the postnatal rodent testis, ER continues to be expressed in Leydig cells 
(Fisher et al. 1997).  ER is still expressed in Leydig cells, immature Sertoli cells, 
spermatogonia, and spermatocytes (Saunders et al. 1998; van Pelt et al. 1999).  ER is 
the predominant ER isoform found in the adult seminiferous epithelium of the rodent, and 
is localized to Sertoli cells, spermatogonia, pachytene spermatocytes and round 
spermatids (Fisher et al. 1997; Saunders et al. 1998)  (Table 1).  More recently Lucas et 
al. (2008) showed that ER was present in the Sertoli cell of adult rodent testis.  Analysis 
of the human ER splice variants in the adult human testis shows that Sertoli cells show 
strong immunostaining for ER2, but less intense staining for ER1.  The ER2 isoform 
also appeared more predominant, in comparison to ER1 in type B spermatogonia, 
perhaps suggesting these cells are less responsive to estrogens (Saunders et al. 2002).  
Both variants were present in type A spermatogonia and pachytene spermatocytes 
whereas round spermatids appeared to have only ER1 protein (Saunders et al. 2002).  
Expression of ER1 in round spermatids could be interpreted to mean that round 
spermatids may be the germ cell type best able to respond to estrogens in the adult human 
testis.  ER expression is also present in mature sperm.  Immunohistochemical detection of 
ERs has been reported for human (Misao et al. 1997; Durkee et al. 1998) and rat sperm 
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(Saberwal et al. 2002).  These studies showed distribution of receptors in both the head 
and flagellum.   
Cooke et al. (1991) determined that efferent ductules were the first site of 
epithelial ER expression in the developing male mouse reproductive tract.  Expression of 
ER was present starting at gestational day 16.  These researchers used steroid 
autoradiography, which has the advantage of indicating a functional receptor capable of 
binding estrogen.  The efferent ductules contained 3-fold more silver grains per epithelial 
cell than more distal parts of the epididymis.  The greater amount of silver grains in the 
efferent ductules indicates a higher concentration of ER in this location.  The 
concentration of estrogen receptors indicates that the efferent ductules of the male 
reproductive tract may be sensitive to increased estrogen levels.  Hess and colleagues 
showed that the adult efferent ductules also express ER and ER with greater 
expression of ER (Hess et al. 1997).  Expression of estrogen receptor is not limited to 
the testis and epididymis. In fact, both estrogen receptors have been localized in the 
developing penis of a number of species, including humans (Crescioli et al. 2003; 
Schultheiss et al. 2003; Dietrich et al. 2004), rodents (Jesmin et al. 2002; Jesmin et al. 
2004) and rabbits (Srilatha and Adaikan 2004).  
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Table 1: Expression of estrogen receptors in postnatal and adult testicular cells (rodent and primate). 
 
   
1.1.C. Estrogen Actions in the Neonatal and Adult Male Reproductive Tract 
 Recent evidence showing production of estrogen by the testis and localization of 
both ER isoforms within the testis have led to the question of estrogen’s involvement in 
testicular physiology, including spermatogenesis (Sharpe 1998; Couse. and Korach 1999; 
O'Donnell et al. 2001; Hess 2003).  Estrogen is produced locally within the testis, 
suggesting a paracrine action on spermatogenesis.  However, it is also possible for 
circulating estrogens to impact testicular function through endocrine feedback 
mechanisms, which would in turn regulate spermatogenesis.  It is has been shown that 
testis is responsive to 17-estradiol as early as 14.5 days post coitum (Montani et al. 
2008).  It is also known that early differentiation and morphogenesis of male reproductive 
organs corresponds to the testosterone surge by fetal Leydig cells that occurs at about 12 
weeks of gestation in humans (Williams-Ashman and Reddi 1991; Klonisch et al. 2004) 
and at late gestation and early neonatal period in rodents (Ward and Weisz 1984; El-
Gehani. et al. 1998).  Alterations in androgenic activity during the critical period of 
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differentiation, resulting from abnormalities in testosterone, 5-reductase, or androgen 
receptor, cause altered development of internal and external genitalia, including 
hypospadias and shorter penis (Gray et al. 2001; Sultan et al. 2001; Kim et al. 2002; 
Foster and Harris 2005).    
 In the 1990s speculation arose concerning the affect of environmental estrogens 
on male fertility.  It was speculated that environmental estrogens may have deleterious 
affects on male fertility if males were inappropriately exposed during gestation or 
postnatally.  It was hypothesized that exposure to estrogen could adversely affect 
reproductive tract development leading to impaired reproductive function in adulthood 
(Sharpe 1993; Sharpe and Skakkebaek 1993).  Exposure to xeno- and phytoestrogens has 
been hypothesized to be involved in a proposed decline in sperm counts in the latter half 
of the twentieth century (Sharpe and Skakkebaek 1993; Auger et al. 1995; Toppari et al. 
1996).  However, environmental estrogens ability to affect human health and male 
fertility has been greatly debated (Daston et al. 1997; Sonnenschein and Soto 1998).    
 Epidemiological studies have suggested links between inappropriate estrogen 
exposure and higher frequency of reproductive abnormalities in men and wild animals 
(Toppariet al. 1996; McLachlan 2001; Safe et al. 2001; Mosconi et al. 2002; Fisher 2004; 
Vidaeff and Sever 2005; Storgaard et al. 2006).  The affects of DES on development and 
function of the male reproductive tract represent the potential consequences of 
inappropriate estrogen exposure during the critical period of differentiation.  DES was 
administered to women from 1940 to 1970 to prevent miscarriages (Bibbo et al. 1977).  
Male offspring of women exposed to DES during pregnancy have higher incidence of 
epididymal cysts, cryptorchidism, hypospadias, and smaller penis (Gill et al. 1979; Swan  
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2000; Klip et al. 2002).  Male offspring born to mothers exposed to DES in utero also 
have a higher incidence of hypospadias, which implies a transgenerational affect (Klip et 
al. 2002; Brouwers et al. 2006).  Pregnant mothers with high intake of phytoestrogens as 
a result of vegetarian diet are more likely to give birth to boys with hypospadias (North 
and Golding 2000).  Laboratory animals exposed neonatally to estrogen also develop 
hypospadias (McLachlan et al. 1975; Kim et al. 2004; Newbold 2004).  Neonatal 
exposure to estrogen at low doses enlarges the adult prostate gland but higher doses have 
the opposite effect (vom Saal et al. 1997; Gupta 2000; Putz et al. 2001; vom Saal and 
Hughes 2005) and perinatal estrogen exposure predisposes the prostate gland to a 
precancerous growth at adulthood by an epigenetic mechanism (Ho et al. 2006).  Studies 
have also reported an affect on male external genitalia due to exogenous estrogen 
administration.  These studies have shown that laboratory animals exposed neonatally to 
estrogen have smaller penises (McLachlan et al. 1975; Zadina et al. 1979; Newbold 
2004) and rabbits treated with bisphenol A had subtunical deposition of fat in the corpora 
cavernosa of their penises (Moon et al. 2001; Goyal et al. 2005).  Male mice treated with 
0.2 g/pup per day of DES on alternate days from postnatal day 2 to 12 showed a 
malformation of the os penis, significant reductions in penile length, diameter, and 
weight, accumulation of fat cells in the corpora cavernosa penis, and significant 
reductions in weight of the bulbospongiosus and levator ani muscles (Goyal et al. 2005).  
Conversely, ERKO males treated with DES developed none of the above abnormalities.  
Failure of ERKO males to develop effects from DES treatment indicates that ER is 
necessary for mediating the harmful affects of neonatal DES exposure in the developing 
penis (Goyal et al. 2007).    These studies indicate that prenatal and/or neonatal exposure 
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to estrogens can have permanent and even transgenerational, deleterious affects on the 
development of male reproductive organs.   
 Neonatal estrogen exposure down-regulates androgen receptor level in male 
reproductive organs (Prins and Birch 1995; McKinnell et al. 2001; Williams et al. 2001; 
Woodham et al. 2003) and lowers plasma testosterone (Sharpe et al. 1998; Atanassova et 
al. 2000).  The neonatal concentration of intratesticular testosterone in rat pups treated 
with DES for postnatal days 1-3 was reduced by 90% at postnatal days 5-8 (Goyal et al. 
2005).  The decrease in intratesticular testosterone at PND 5-8 correlates with the 
developmental period when stromal cells start differentiation in the rat penis (Murakami 
1986, 1987) suggesting a role for estrogen-induced lower androgen action in inducing 
penile abnormalities by reprogramming stromal cell differentiation.  These alterations in 
androgenic activity during the critical period of differentiation also lead to the deformities 
in male reproductive tract development which are seen in DES-treated animals and 
human males born to mothers given DES.  It has also been shown that testosterone, when 
given with DES, is capable of preventing the abnormalities induced by DES (Rivas et al. 
2003).  Indicating testosterone may be protective against the affects of DES. 
  Gross morphological abnormalities are not the only defects seen in animals 
treated with estrogen.  Neonatal exposure to relatively low concentrations of DES have 
been shown to negatively affect the development of Sertoli cells (Sharpe et al. 1998; 
Atanassova et al. 1999).  Although it has been argued that xeno- and phytoestrogens may 
be involved in the decline in sperm counts in the latter half of the twentieth century, some 
researchers have shown that estrogens may exert stimulatory affects on early germ cell 
development in the testis of several animals (Kula 1988; Slowikowska-Hilczer and Kula 
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1994; Kula et al. 1996; Li et al. 1997; Miura et al. 1999).  The mixed results of estrogen 
exposure fuel the debate over environmental estrogens’ involvement in the decline of 
male fertility.  
 The efferent ductules have the highest concentration of ER in the male 
reproductive tract, indicating its sensitivity to estrogen stimulation.  The efferent ductules 
are a series of tubules that connect the rete testis to the epididymis.  The efferent ductules 
function to concentrate the sperm by absorbing 90% of the fluid leaving the testis (Hess 
2000, 2003; Hess et al. 2001).  The major cell types in the efferent ducts are nonciliated 
and to a lesser extent ciliated cells, which chiefly function in absorption/ion secretion and 
mixing of the luminal contents, respectively (Lee et al. 2001).   Aquaporins expressed in 
the efferent ductules mediate water transport out of the lumen, decreasing the water 
content of the semen and thereby increasing sperm quality (Wellejus et al. 2008).  
Interestingly similar defects are seen in the efferent ductule of males treated with 
exogenous estrogens and ERKO males.  Hess and colleagues conducted in vitro ligation 
experiments and found the ability of the ERKO efferent ductules to reabsorb fluid was 
greatly impaired (Hess et al. 1997).  ERKO efferent ductules show numerous structural 
differences compared to wild-type ductules, all of which are consistent with a decrease in 
fluid reabsorption (Hess 2000, 2003; Hess et al. 2000).  A molecular target of estrogen 
action in the efferent ductules appears to be Na+/H+ exchanger-3, and the ER-dependent 
expression of Na+/H+ exchanger-3 in ERKO mice is effected (Lee et al. 2001).  Altered 
Na+/H+ exchanger-3 expression has downstream affects on the expression of other 
proteins central to fluid reabsorption (Zhou et al. 2001).  Structural and functional 
development of efferent ductules are susceptible to changes after estrogen exposure 
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during early life, and this has been associated with downregulation of aquaporin-1 
expression in adult rats after neonatal exposure to DES (Fisher et al. 1998; Fisher et al. 
1999).  In contrast neonatal exposure to DES causes an upregulation in aquaporin-9 
expression (Wellejus et al. 2008).  Neonatal exposure to highly potent estrogenic 
substances causes dilation of the rete testis and fluid accumulation, permanent reductions 
in the water channel protein aquaporin-1, changes in the cell- and region-specific 
expression of ER protein in the male reproductive tract and compromised 
spermatogenesis in adulthood (Bibbo et al. 1977; Gill et al. 1977; 1979; Aceitero et al. 
1998; Fisher et al. 1998; 1999; Atanassova et al. 2001).  The upregulation of aquaporin-9 
may be attributed to the widening of the efferent ductule lumen caused by inhibited fluid 
reabsorption and increased intratubular pressure.  These studies highlight the fact that the 
development of the efferent ductules is a target for estrogen action, with either too little 
or too much being detrimental to its function.  The mechanisms by which estrogen 
exposure and deficiency impair efferent ductule development and function is not clear, 
but may relate to estrogen exposure changing patterns of androgen receptor and estrogen 
receptor expression in the male reproductive tract.  Changing patterns of androgen 
receptor and estrogen receptor expression may interfere with the androgen: estrogen 
balance, as well as the balance of ER subtypes expression, that is likely important in the 
function of the efferent ductules.  Rivas and colleagues (2002) showed that combined 
administration of DES plus GnRH antagonist or flutamide induced significantly greater 
distension/overgrowth of the rete testis and efferent ducts and a reduction in epithelial 
cell height of the efferent ducts than did DES administration alone.  The findings from 
this study suggest that reduced androgen action sensitizes the reproductive tract to 
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estrogens, demonstrating that the balance in action between androgens and estrogens, 
rather than their absolute levels, may be of fundamental importance in determining 
normal or abnormal development of some regions of the male reproductive tract (Rivas et 
al. 2002).  Another explanation for the similar effects of neonatal estrogen exposure and 
deficiency is that inappropriate estrogen exposure may lead to down-regulation of ERs,  
resulting in an estrogen deficiency syndrome similar to that seen in ERKO mice.  
Developmental exposure to DES has been shown to decrease the ER levels in rat uterus 
in adulthood (Medlock et al. 1988; Medlock et al. 1991; Medlock et al. 1992).  Similarly, 
studies in testis suggest that neonatal DES exposure lead to down-regulation of ER and 
AR, but an increase in ER (Tena-Sempere et al. 2000), perhaps suggesting a permanent 
change in either estrogen responsiveness, or in estrogen-dependent gene expression. 
 
 
1.2: GENISTEIN 
 
1.2.A. Properties of Genistein 
 Phytoestrogens are classically defined as estrogenic compounds found in plants.   
Genistein (4’, 5, 7 – trihydroxy-isoflavone) is one of the most abundant phytoestrogens.  
It is present in many plants that are important components of human and animal diets 
(Farnsworth et al. 1975; Setchell et al. 1984; Mazur and Adlercreutz 2000), and is the 
most estrogenic compound found in soy (Montani et al. 2008).    Phytoestrogens bind to 
the estrogen receptor and induce specific estrogen-responsive gene products.  
Phytoestrogens can exert estrogenic affects on the central nervous system, induce estrus, 
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stimulate growth of the genital tract of female animals (Lieberman 1996) and stimulate 
ER-positive breast cancer cell growth (Kurzer and Xu 1997).   
Phytoestrogens are divided into three classes based on their chemical structure.  
These three groups are isoflavonoids, lignans, and coumestans (Kurzer and Xu 1997; 
Setchell 1998; Miniello et al. 2003).  Genistein, daidzein, glycitein, biochanin A, and 
formononetin comprise the isoflavonoids.  Isoflavonoids are primarily found in soybeans 
(Coward et al. 1993; Wang and Murphy 1994; Miniello et al. 2003).   Soybeans contain 
the isoflavonoids genistein and daidzein as inactive glycosides or as metabolically active 
aglycones (Axelson et al. 1984; Kurzer and Xu 1997) (Figure 1).  The malonyl and acetyl 
glycosides are susceptible to heat and readily convert to the more stable -glycoside 
(Barnes et al. 1994); therefore, depending on the extent of processing of the soybean, the 
relative proportions of these conjugates can vary considerably among different soy-foods 
(Coward et al. 1993; Wang and Murphy 1994; Coward et al. 1998).  In soy-protein 
formulas the isoflavonoids are present mainly as glycosides of genistein, which account 
for more than 65% of the total isoflavones (Miniello et al. 2003).  The systemic 
bioavailability of genistein is much greater than that of daidzein and the bioavailability of 
these phytoestrogens is greater when ingested as glycosides rather than the active 
aglycones (Setchell et al. 2001).  Gut microflora strongly affect the conversion of plant 
precursors, such as glucosylated genistein, into active aglycone genistein (Axelson and 
Setchell 1981; Setchell et al. 1984).  The metabolic pathways of daidzein and genistein 
catabolism in humans were originally proposed by Setchell and Adlercreutz (1988) and 
has been expanded recently by Joannou et al (1995), based on the isoflavone metabolites 
found in human urine (Figure 2).  Daidzein is metabolized to dihydrodaidzein, which is 
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further metabolized to both equol and O-desmethylangolensin (O-DMA).  Genistein is 
transformed to dihydrogenistein and is further metabolized to 6-hydroxy -O- DMA 
(Kurzer and Xu 1997).  Isoflavone and lignan absorption and utilization require a series 
of deconjugation and conjugation steps.  Genistein absorption initially occurs passively 
through diffusion, because the rate of absorption increases with the increased intake of 
genistein (Sfakianos et al. 1997).  Absorption is facilitated by hydrolysis of the sugar 
moiety by human gut bacterial -glucosidases, gastric hydrochloric acid, and -
glucosidases in foods (Kelly et al. 1993).  Cleavage of the carbohydrate portion releases 
the biologically active aglycone which is a heterocyclic phenol structurally resembling 
estrogens (Murkies et al. 1998) (Figure 3).  Genistein is made of three rings: a phenolic 
B-ring bound to the 3 position of the pyran C-ring, and adjacent to the C-ring is the 
phenolic A ring.  The 4’-hydroxy group on the B-ring in combination with the 7’-
hydroxy group are responsible for the estrogenicity of genistein, while the 5’-hydroxy 
and 4-keto groups on the A/C ring are responsible for the growth inhibitory action of 
genistein (Zava and Duwe 1997).  These heterocyclic phenols are capable of binding both 
ER and ERand sex-hormone binding globulins (Chen and Rogan 2004)Unlike E2 
which has similar affinity for both ERs, genistein and daidzein have greater affinity for 
ER than ER (Cooke et al. 2006).  After absorption in the small intestine, isoflavones 
and lignans are conjugated with glucuronic acid and sulfate by hepatic phase II enzymes 
(UDP-glucuronosyltransferases and sulfotransferases).  Like endogenous estrogens, these 
conjugates are excreted through both urine and bile and undergo enterohepatic 
circulation.  After excretion into bile, conjugated isoflavones and lignans can be 
deconjugated once again by gut bacteria.  Deconjugation may promote reabsorption, 
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further metabolism, and degradation in the lower intestine (Setchell and Adlercreutz 
1988; Xu et al. 1995).  The biological affect exerted by these estrogen-like compounds 
has been greatly debated. 
 Phytoestrogens may have beneficial affects on some types of cancer, 
cardiovascular health, brain function, alcohol abuse, osteoporosis and menopausal 
symptoms (Hirayama 1984; Tajima and Tominaga 1985; Lee et al. 1991; Goodman et al. 
1997), but also can have adverse effects on reproductive systems (Kurzer and Xu 1997; 
Bingham et al. 1998).  The phytoestrogen coumestrol causes infertility in sheep, a 
condition known as clover disease (Bennetts et al. 1946; Bennetts and Underwood 1951; 
Braden et al. 1967; Shutt and Braden 1968), and daidzein significantly decreases 
expression of ER and AR mRNAs in rat uteri (Bennetts and Underwood 1951; Diel et 
al. 2000). 
 Asian populations which consume diets high in soy are estimated to ingest 
between 30 and 50 mg/day of soy isoflavones (Adlercreutz et al. 1993; Kimira et al. 
1998) equivalent to about 1.5 mg/kg/day of isoflavone.  Ingestion of 1.5 mg/kg/day of 
isoflavone results in a mean plasma concentration of genistein of 406.8 nmol/L (Uehar et 
al. 2000).  Infants consuming soy based formulas are exposed to a much higher 
concentrations of genistein than adults on a soy containing diet.  Leading infant formulas 
such as Nursoy, Isomil, Alsoy, and Prosbee have isoflavone contents ranging from 32-47 
mg of isoflavones/L (Setchell et al. 1997).  It has been estimated that soy-protein infant 
formulas contain 87 ±3 g/g of genistein (Irvine et al. 1998).  Infants consume 6 – 11 
mg/kg/day of isoflavones, which is greater than that consumed by adults on a high-soy 
diet (1.5 mg/kg/day) (Le et al. 2004).   Ingestion of 11 mg/kg/day of isoflavone results in 
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a plasma concentration of genistein of 2.53 mol/L (Setchell et al. 1998).  The plasma 
concentration of genistein in soy fed infants is 13,000 – 22,000-fold higher than 
endogenous plasma estradiol concentrations in early life (Setchell et al. 1997; 1998).  It is 
also 16 times higher than plasma genistein concentrations found in Japanese adults.  
Irvine et al. (1998) reported that infants as young as 4 weeks old can digest, absorb, and 
excrete genistein and daidzein from soy-based formulas as effectively as adults 
consuming soy products.  It is also known that infants have a higher concentration of 
genistein aglycone, or the active form of genistein (Chang et al. 2000; Doerge et al. 
2002). 
 Soy-protein formula was first described in 1909 as a cow-milk substitute (Merritt 
and Jenks 2004).  Its use as a milk substitute for infants with cow-milk allergies was not 
introduced until 1929.  The first soy-protein formulas on the market are referred to as first 
generation formulas.  These formulas had an unpleasant caramel-like color and caused 
mineral deficiencies and carbohydrate intolerance.  A second generation formula was 
developed in the 1960s and was based on a soy protein isolate of at least 90%.  More 
importantly, the distribution of nutrients in these soy protein formulas is quite similar to 
that in cow-milk formulas (Miniello et al. 2003).  Although these second generation soy-
protein formulas are more nutritiously sound and have corrected some of the problems 
with the first generation formulas, the formulas still contain plant-derived estrogens, 
known as phytoestrogens.  The presence of these phytoestrogens could have short- and/or 
long-term affects on the development of the infants that receive them.  In the United 
States, it is estimated that 18 -25% of infants are given soy-protein formulas (Strom et al. 
2001; Miniello et al. 2003). About 540,000 - 750,000 infants/year have consumed soy-
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protein formulas in the United States.  It is estimated that some 20,000,000 infants in the 
United States have consumed soy infant formula since the 1960s (Strom et al. 2001).   
The use of soy-infant formula was originally advocated or prescribed only for 
infants exhibiting signs of intolerance to cow’s milk.  However, it is sometimes used as 
the breast milk substitute of choice, and is frequently used within the first months of life 
(Polack et al. 1999).  Although the soy isoflavones are weak estrogens, soy formula 
contains so much of them that estimates of daily estrogenic dose per kilogram body 
weight are equivalent to 0.01 to > 1 contraceptive pill per day, depending on the potency 
estimate used (Klein 1998; Chen and Rogan 2004).  Also, adults rarely exceed 25% of 
calories from soy (Baird et al. 1995), however,  infants fed soy formula get 100% of their 
calories from soy.  Concerns have been expressed as to whether or not the high 
isoflavonoid phytoestrogen content of these soy formulas pose adverse affects to the 
developing infant.  It has been hypothesized to be harmful for development of the male 
reproductive system and subsequent adult fertility (Chen and Rogan 2004).   Soy 
formulas are given during a developmental period when humans have low endogenous 
estrogen concentrations  It has previously been shown that isoflavonoid phytoestrogens 
can exert a range of affects in animals such as birds, rodents, cheetahs, and sheep (Alpert 
1976; Leopold et al. 1976; Setchell et al. 1987; Irvine et al. 1995; Whitten et al. 1995; 
Whitten and Naftolin 1998).  The high concentrations of isoflavonoid phytoestrogens are 
likely to exert some biological effects in human infants. 
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Figure 1: Chemical structures of the isoflavones found in soybeans.  Daidzein and genistein are also 
present as acetylglucosides (6" - O - acetyldaidzin,  6"- O - acetlygenistin) and malonylglucosides (6" 
- O - malonyldaidzin, 6" - O - malonylgenistin) (Kurzer, M. S. and Xu, X. 1997). 
 
 
 
Figure 2: Proposed metabolic pathways for the catabolism of daidzein and genistein by human gut 
bacteria.  The formation of O-DMA from daidzein and 6'-hydroxy-O-DMA from genistein likely 
involves several reduction reactions.  The formation of equol from dihydrodaidzein may go through 
reduction, dehydration, and further reduction reactions (Kurzer, M. S. and Xu, X. 1997). 
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Figure 3: Chemical structure of estradiol-17 and genistein. 
 
1.2.B. Binding Affinity 
 Similarity between genistein and estrogen’s chemical structure and genistein’s 
affinity for ER has lead to the concern that genistein can cause deleterious effects on 
reproductive development and function in both humans and wildlife.  To understand the 
genistein effects in vivo, it is necessary to identify the interaction of genistein with 
plasma sex steroid binding proteins.  These proteins such as -fetoprotein (AFP) bind 
particular steroids with high affinity and specificity and are believed to be important 
modulators of endogenous steroid hormone action (Hammond 1995).  If a large amount 
of AFP is present this will reduce the amount of free estradiol to very low concentrations, 
reducing its biological activity by restricting its availability to target cells.  However, 
binding of exogenous estrogens to AFP would reduce the biological activity of the 
exogenous estrogen, while displacing biologically active estradiol.  If the exogenous 
estrogens are incapable of binding AFP this would allow their action on target cells, 
while AFP sequesters the naturally present estradiol.  AFP is found in the amniotic fluid 
and in the blood of fetuses and neonates, it binds estradiol with high affinity and high 
specificity (Payne and Katzenellenbogen 1979; Garreau et al. 1991).  Some studies have 
suggested that the binding of estradiol by AFP in the perinatal period is of critical 
importance in preventing early estrogen exposure from inducing inappropriate sexual 
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differentiation of the brain of the female (Milligan et al. 1998).  However, a study 
conducted by Milligan and colleagues showed that genistein does not bind AFP (Milligan 
et al. 1998).  Genistein’s inability to bind AFP indicates that genistein may be capable of 
binding ER at a time when AFP is binding endogenous estrogen.   
Immediately after birth hormonal imprinting takes place.  Hormonal imprinting 
occurs when the hormone first begins signaling through its target receptor.  Hormonal 
imprinting is necessary for the normal maturation of the receptor – signal transduction 
system.  Although each receptor is sensitive to imprinting, the steroid receptor 
superfamily is especially sensitive in the perinatal critical period (Csaba 2000).  During 
the perinatal critical period if genistein is present and binds the receptor instead of the 
target ligand E2 faulty imprinting occurs.  Faulty imprinting results in life-long 
consequences that can result in abnormalities at the receptor, morphological, 
biochemical, genetic and behavioral levels in adult animals (Bern et al. 1973; Bern et al. 
1975; Iguchi 1992; Nelson et al. 1994; Karabelyos and Csaba 1998). 
 Similarities in genistein’s chemical structure to E2allows it to bind both estrogen 
receptors (Kuiper et al. 1998).  However, because the chemical structure of genistein is 
not identical to E2 the binding is not identical.  Although E2 has similar binding affinity 
for both estrogen receptors, genistein has been shown to bind ER with greater affinity 
(Cooke et al. 2006).  Genistein has been reported to bind the ER in cytosol preparations 
of sheep uteri with relative binding affinities of 0.9% of E2 (Shutt and Cox 1972).  
Genistein has also demonstrated binding to cytoplasmic ER present in the pituitary gland 
and the hypothalamus of the ewe (Molteni et al. 1995).    
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Antiestrogenic affects of phytoestrogens have also been observed.  It has been 
proposed that phytoestrogens may be able to compete effectively with endogenous 
mammalian estrogens for binding to the ER and prevent estrogen- stimulated growth in 
mammals (Adlercreutz et al. 1995).  Binding of phytoestrogens to the ER instead of 
endogenous estrogens may also result in interference with the release of gonadotropins 
and interruption of the feedback-regulating system of the HPT axis.  There are some data 
supporting the idea that genistein can bind ER instead of endogenous estrogen.  Genistein 
and coumestrol have competitively suppressed the binding of [3H]estradiol to ER when 
added to rat and human mammary tumor tissue (Verdeal et al. 1980). 
 A study conducted by van Lipzig and collegues (2004) to predict the ligand 
binding affinity and orientation of xenoestrogens to the estrogen receptor determined that 
the energetically favorable orientation of genistein in the ER is different from its 
orientation in the crystal structure of ERas proposed by Pike et al. (1999).  These 
authors proposed that the difference in genistein’s binding affinity for the two estrogen 
receptors could account for genistein being an agonist for ER and only a partial agonist 
for ER Pike and colleagues identified the structure of the ligand-binding domain of 
ER in the presence of genistein.  The overall structure of the ER-ligand binding 
domain is very similar to that previously reported for ER (Brzozowski et al. 1997).  
Genistein was found to be completely buried within the hydrophobic core of the protein 
and binds in a manner similarly to E2.  However, in the ER – genistein complex, the AF-
2 helix does not adopt the distinct ‘agonist’ position, but instead, lies in a similar 
orientation to that induced by ER antagonists.  Failure of the AF-2 helix to adopt the 
distinct agonist position after genistein binding to ER is consistent with genistein’s 
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partial agonist character in ER (Pike et al. 1999).  Genistein is not limited to binding 
only the ER.  Genistein is capable of binding other cellular proteins. 
   It is possible that tyrosine phosphorylation plays an important role for cell 
proliferation and cell differentiation.  Protein tyrosine kinases (PTKs) are oncogene 
products that catalyze phosphorylation of their own tyrosine residues as well as those in 
other proteins (Hunter and Cooper 1985).  Isoflavones, especially genistein have been 
shown to inhibit cellular PTKs (Chang and Geahlen 1992; Boutin 1994).  In vitro 
experiments conducted by Akiyama et al., (1987) with the epidermal growth factor 
receptor in intact A431 cells, show that genistein inhibits the receptor tyrosine 
autophosphorylation and tyrosine phosphorylation of both natural and artificial 
compounds.  PTK inhibition has been proposed to explain the growth-inhibiting affects 
of genistein in a number of different human cancer cells.  Genistein has been shown to 
induce terminal differentiation and inhibit proliferation in a dose-dependent manner in 
human leukemia and melanoma cells (Constantinou et al. 1990; Constantinou and 
Huberman 1995).  However, genistein inhibits tyrosine kinases only at 
supraphysiological concentrations.  These concentrations, typically 100 mol/L, are 
many times greater than what is obtained through consumption of dietary genistein. 
 DNA topoisomerases are enzymes that catalyze topologic changes in DNA and 
are required for DNA replication (Champe and Harvey 1987; Granner 1990).  Genistein 
has been shown to inhibit both topoisomerase I and II activity (Okura et al. 1988; 
Markovits et al. 1989; Constantinou et al. 1990; Kiguchi et al. 1990).  Genistein has also 
been shown to inhibit the relaxation of pBR322 (supercoiled) DNA catalyzed by 
topoisomerase II at concentrations greater than 7.4 M (Okura et al. 1988).  Genistein is 
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able to induce topoisomerase II – mediated double-strand breaks, which suggests that 
genistein may stabilize the topoisomerase II – DNA complex, allowing the breaks to 
occur but preventing them from being resealed (Constantinou et al. 1990). 
Genistein’s estrogenic affects either as an estrogen agonist or antagonist have 
been hypothesized to have an effect on the male reproductive system development when 
consumed during the developmentally critical period. 
   
1.2.C. Reproductive System Effects 
 Fetal testes are responsive to genistein as well as E2 by gestational day 14.5 
(Montani et al. 2008) which makes them a target for gestational and neonatal exposure to 
genistein.  Genistein’s affects on male reproductive tract development have been 
extensively studied using animal models.  However, data from human infant exposure to 
soy-based formulas is lacking.  Current research to study the affects of genistein in 
animals employs two main methods of genistein administration: maternal administration, 
or direct injection of the pups. Both of these methods do not properly mimic the form of 
exposure seen in human infants.  Human exposure to genistein is primarily through the 
diet, (e.g,. soy infant formula).  A neonatal mouse receives 100% of their nutrients from 
the mother’s milk.  Previous studies have shown that exposure of the mother to genistein 
in the diet has limited lactational transfer to the pups (Lewis et al. 2003; Doerge et al. 
2006).  For example pregnant dams exposed to 16 mg/kg of genistein orally during 
lactation had a serum circulating concentration of genistein of 1.8 g/mL but the 
concentration found in the milk was only 0.04 g/mL which is 45 times less than 
circulating concentrations in the dam (Doerge et al. 2006).  The inefficient transfer of 
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genistein through the milk makes maternal dosing inefficient and necessitates the dam be 
dosed with toxic concentrations to achieve a concentration in the milk that mimics human 
exposure concentrations. 
 Human studies on soy formulas have mainly focused on nutritional status, with 
only one on long-term safety.  The long-term study was conducted by Strom et al. (2001).  
In the study conducted by Strom and colleagues, they interviewed 811 subjects in their 
twenties or early thirties who, as infants, were given soy formula (120 males and 128 
females) or cow-milk formula (295 males and 268 females).  They determined that there 
was no difference in the answers to general questions about health and reproduction 
between the two treatment groups.  They did find that women fed soy infant formula 
reported a longer duration of menstrual bleeding (about 8 hours) and greater discomfort.  
These researchers also noted that individuals given soy infant formula reported more use 
of asthma or allergy drugs and a greater tendency for sedentary activities. 
 Studies conducted using animal models tend to show more drastic effects of 
genistein treatment.  Studies conducted by Newbold et al ( 2001) reported that outbred 
neonatal CD-1 mice treated by subcutaneous (sc) injections with genistein (50 
mg/kg/day) on postnatal days 1 – 5 had prevalence of 35% of uterine adenocarcinoma at 
18 months of age.  The same lab (Jefferson et al. 2002), also reported an increased 
incidence of multi-oocyte follicles in females treated by sc injections on postnatal days 1 
– 5 with 10, or 100 mg/pup/day (~ 5, and 50 mg/kg/day).  Other studies have also shown 
an advanced mean day of vaginal opening by as many as 4 days (Lewis et al. 2003).  
Advanced vaginal opening indicates an accelerated rate of puberty onset.  Affects of 
genistein treatment are not exclusive to females.  A feeding study in twin marmoset 
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monkeys showed that the twin fed with soy formula for ~ 8 hours each weekday and 2 
hours on weekends from postnatal days 4-5 until postnatal days 35-45 had low plasma 
testosterone concentrations (1.3 ± 2.1 ng/ml) compared with the twin that was fed cow-
milk formula (2.8 ± 3.9 ng/ml) (Sharpe et al. 2002).  No difference in testis weight was 
noted in these twins.  However, the twin fed soy infant formula had higher Leydig cell 
counts.  Similar results have also been seen in rodent models.  Time-bred Long-Evans 
dams were fed diets containing 0, 5, 50, 500, or 1000 ppm of soy isoflavones from 
gestational day 12 until weaning at PND 21.  Males from the highest exposure group 
exhibited elevated serum concentrations of sex steroid hormones androsterone at PND 21 
and testosterone at PND 90, although steroidogenesis was decreased in individual Leydig 
cells (Akingbemi et al. 2007). 
 In vitro studies have also shown that genistein is capable of promoting sperm 
capacitation, acrosome reaction, and fertilizing ability in mice.  However, in vivo studies 
in mice do not support this in vitro data.  Fielden and colleagues (2003) dosed C57BL/6 
dams with genistein from gestational day 12 to postnatal day 20.  Offspring from these 
dams were assessed for testicular growth, sperm count and motility, and sperm fertilizing 
ability in vitro.  These researchers found no significant treatment related affect on male 
offspring body weight, anogenital distance, seminal vesicle weight, or testis weight.  
They also found no significant affect on sperm count, the percent of motile sperm or the 
number of motile sperm at any age.  However, they did find that male offspring from 
dams treated with the highest dose of genistein (10 mg/kg/d) had a significantly increased 
in vitro fertilizing ability.  They found that these males had a 17% increase in fertilizing 
ability on PND 105 and 315 (Fielden et al. 2003).  Wisniewski et al. (2003) observed 
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demasculinization of the reproductive system in rat pups after in utero and lactational 
exposure to genistein (0, 5, 300 ppm from gestational day 1 – PND 21).  These animals 
had smaller testis size, fewer animals with preputial separation at postnatal day 40, lower 
plasma testosterone concentrations (3.72 ± 0.55, 1.76 ± 0.31, 2.23 ± 0.42 ng/ml in 0, 5, 
and 300 ppm, respectively).  In addition, fewer males were capable of ejaculation at PND 
70.  These researchers did note however, that sperm counts were not significantly altered 
between any of the groups.  It has also been shown that testes from male ICR mice that 
were exposed to genistein (1000 g/mouse/day), starting 1 day after birth for 5 days, had 
a decrease in the mRNA level of ER  and AR (Adachi et al. 2004).  In another study, 
dosing neonatal rats by subcutaneous injection with 4 mg/kg/day of genistein from PND 
2 – 12, researchers found a minor but significant decrease in epithelial cell height of the 
efferent ducts at day 18.  Decrease in efferent duct epithelial cell height was transient and 
was not apparent by PND 25.  Treatment with genistein did not affect the expression of 
AQP-1 or rete testis morphology (Fisher et al. 1999).  In another study using neonatal rats 
to look at the effects of genistein on the physiology and morphology of the hypothalamus 
and pituitary, rats were injected with 100 g – 1000 g from PND 1 -10.  These animals 
were then castrated at PND 21.  Males exposed to 100 g of genistein showed increased 
pituitary response to GnRH.  The males exposed to 1000 g of genistein showed 
decreased tonic LH or attenuated GnRH- stimulated LH secretion.  Genistein treatment 
did not have an affect on the volume of the sexually dimorphic nucleus of the preoptic 
area (Faber and Hughes 1991).  Prenatal exposure of genistein has been shown to 
influence sexual differentiation (Kurzer and Xu 1997).  Neonatal subcutaneous injections 
of 10 – g genistein to rat pups was associated with increased pituitary response to 
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gonadotropin releasing hormone, increasing genistein was associated with decreasing LH 
secretion on postnatal days 1 – 10 (Faber and Hughes 1993).   
Genistein is not the only estrogenic chemical infants are exposed to during a 
developmentally critical stage of their lives.  Soy-protein formulas are typically 
administered to infants in plastic baby bottles which may not be as innocuous as once 
thought.  It is known that these plastic baby bottles and the containers which store the 
soy-protein formula contain the xenoestrogen bisphenol A. 
 
1.3: BISPHENOL A 
 
1.3.A. Properties of Bisphenol A 
Bisphenol A (BPA; 4, 4’-isopropylidenediphenol) is a product of industrial 
society produced in large quantities worldwide.  The amount of BPA produced is greater 
than 3.7 million metric tons/year and estimated to increase by 6 to 7% each year 
(Anonymous 2005).  Based on these estimates the amount of BPA production currently 
(2008) is between 4.41 million metric tons and 4.53 million metric tons per year.  BPA is 
synthesized by the combination of two equivalents of phenol with one equivalent of 
acetone.  BPA was first synthesized in 1891 by A.P. Dianin (Vandenberg et al. 2009).  
Industrial production of BPA uses an acid-catalyzed condensation reaction to minimize 
by-products.  BPA is the key building block used in the manufacture of two types of 
polymers used in food contact articles, specifically, polycarbonate polymers and epoxy-
based enamels and coatings.  Polycarbonate plastic, first made in 1952, is a light-weight 
high performance plastic.  Polycabonate plastic possesses several qualities that make it a 
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favorable choice for many uses.  Its durability, shatter-resistance and heat-resistance 
make it an ideal choice for tableware as well as reusable bottles and food storage 
containers that can be conveniently used in the refrigerator and microwave (Biles et al. 
1997).  Epoxy polymers are resistant to solvents and can bond to a variety of substrates, 
especially metals (Biles et al. 1997).  These properties make epoxy resins a popular 
choice for use in enamel coatings on the food contact surfaces of metal food and 
beverage cans.  Many of the epoxy resins are synthesized by the condensation of BPA 
with epichlorhydrin to create BPA diglycidyl ether (Vandenberg et al. 2009).  Bisphenol 
A plastics and resins are used in the manufacture of milk and food containers, baby 
formula bottles, water carboys (Biles et al. 1997), the interior lining of food cans 
(Brotons et al. 1995), and dental resins and composites (Olea et al. 1996; Staples et al. 
1998).  These food contact substances have been regulated for many years pursuant to 
regulations published in Title 21 of the Code of Federal Regulations (CFR).  
Polycarbonate (PC) polymers are regulated in 21 CFR 177.1580. Epoxy-based enamels 
and coatings are regulated in 21 CFR 175.300 (b) (3) (viii), 21 CFR 177.1440 and 21CFR 
177.2280 (FDA 2008).   
Polymeric reactions do not go entirely to completion, which allows BPA to leach 
from these materials during use of the product.  The ester bond linking BPA molecules in 
polycarbonate and resins is subject to hydrolysis, resulting in leaching of BPA monomer 
even from new polycarbonate into water at room temperature (Howdeshell et al. 2003).  
The rate of leaching due to hydrolysis of the ester bonds increases as temperature 
increases in response to acidic or basic conditions (Carey 2003).  Polycarbonate is 
marketed as being highly durable, which prolongs its use in consumer households.  
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However, as polycarbonate begins to show signs of wear, the rate of leaching can 
increase over 1000-fold relative to the rate of leaching from new products (Howdeshell et 
al. 2003).  Many studies have been conducted showing the ability of BPA to leach from 
these materials under normal usage conditions (Brotons et al. 1995; Biles et al. 1997; 
Biles et al. 1997).   
Bisphenol A has been shown to migrate from epoxy can coatings into infant 
formula liquid concentrates.  A study conducted by Biles et al. (Biles et al. 1997) of all 
the major manufacturer’s formulas showed a range of BPA in the infant formula 
concentrates of 0.1 ppb – 13.2 ppb.  The amount actually consumed would be less 
however, because manufacturer directions call for a 1:1 (V/V) dilution of the concentrate 
with water.  The study conducted by Biles and colleagues shows that BPA recoveries are 
higher in soy-based infant formulas than milk-based infant formulas (104% vs. 86%) 
(Biles et al. 1997).  The results from the study conducted by Biles and colleagues indicate 
that infants fed soy-based infant formulas would receive a higher amount of BPA than 
infants fed cow’s milk-based infant formulas.  In an FDA report by Biles and colleagues 
(Biles et al. 1997) the amount of BPA in a variety of polycarbonate baby bottles was 
determined after mimicking conditions of repeated use, and typical use.  These 
researchers found that BPA residues varied widely in the different polycarbonate baby 
bottles tested (7.4 – 46.6 g/g).  They found that with repeated use there was an initial 
high migration rate of BPA (4.9%), but the migration decreased with repeated use and 
leveled out with each subsequent interval in the experiment (1.7%, 0.9%, 0.9%).  These 
researchers also tested the migration of BPA after conditions that would mimic typical 
use.  They found that the migration amount, when converted by using the internal surface 
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area in contact with the food (249 cm2) when a bottle is completely filled (250 mL), was 
equivalent to 2ng/g in formula (Biles et al. 1997).  These conditions are probably more 
likely to simulate the actual use of such articles in the home and show that such usage is 
likely to result in transferring little if any BPA into food.  Actual migration of BPA from 
reusable items may exceed the available residual levels because additional BPA can be 
formed through polymer hydrolysis with repeated heating operations with aqueous foods 
(Lieng-Huang 1965; Gardner 1979; Gachter and Muller 1990).   
The FDA found that the small amount of BPA that migrated into food from the 
use of PC-based polymers and BPA-based epoxy coatings result in a cumulative daily 
intake for adults of 11 g/ person/ day.  The cumulative daily intake of BPA for adults 
was estimated based on: 1) the migration level of BPA into food, or into food-simulating 
solvents, under the most severe conditions of use (i.e. time and temperature), and 2) 
information on the types of food contacted, the fraction of the diet that would come into 
contact with that type of food contact material, and whether the finished food contact 
article would be intended for single or repeated use.  The FDA’s evaluation also 
considered that the use of can enamels in infant formula packaging and the use of PC 
baby bottles results in an estimated daily intake of 7 g/infant/day (FDA 2008).  Other 
researchers have estimated that an infant aged 1 to 2 months would ingest 0.035 mg/day 
of BPA and  an infant aged 4 to 6 months would ingest 0.05 mg/d of BPA (Willhite et al. 
2008).   A directive of the European Union has established a specific migration limit in 
food of 3 mg BPA/kg food (Brotons et al. 1995).  At the time the migration limit was set 
by the European Union, BPA was of little concern and thus given a higher tolerance 
limit.  However, concerns about BPA’s toxicity have been heightened because BPA was 
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shown to be estrogenic (Krishnan et al. 1993), and have a chemical structure similar to 
that of the potent synthetic estrogen DES (Roy et al. 1997; Schonfelder et al. 2002). 
BPA has been detected in virtually everyone in the United States, Europe, and 
Asia who were examined, always within the range of approximately 0.1 – 10 ng/ml in 
both blood and tissue, and within the same range in urine after conjugation (vom Saal 
2006).  BPA is rapidly metabolized suggesting that continuous human exposure to this 
ubiquitous chemical must be occurring throughout the world.  Findings published by the 
CDC from the 2003 – 2004 National Health and Nutrition Examination Survey revealed 
that 93% of people in the United States had detectable concentrations of BPA in their 
urine.  Surprisingly, concentrations in children were significantly higher than 
concentrations in adolescents, who had higher concentrations than adults (Calafat et al. 
2008).  Human exposure to BPA occurs through multiple routes.  However, oral exposure 
is considered the major route of exposure.  Oral exposure occurs due to the leaching of 
BPA from polycarbonate containers and from the plastic linings of cans containing food 
and beverages.  BPA is also detected in indoor air primarily associated with dust, which 
indicates exposure can occur through inhalation.  BPA is also found in streams and rivers, 
and leaches from landfills, suggesting that BPA is a common contaminant of water used 
for drinking and bathing (Taylor et al. 2008).  
The Children’s Total Exposure to Persistent Pesticides and Other Persistent 
Organic Pollutants study conducted in 2000 and 2001 in the states of North Carolina and 
Ohio, investigated the exposures of 257 preschool children and their primary caregivers 
to a variety of anthropogenic organic chemicals that were likely to be found at low 
concentrations in their everyday environments (Wilson et al. 2004).  In the study 
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conducted by Wilson and collegues (2004) BPA was detected in > 50% of indoor air, 
hand wipe, solid food, and liquid food samples, and the route of exposure was 
predominantly through dietary ingestion (99%). 
 BPA is absorbed from the gut where it is conjugated by enterocytes and 
hepatocytes to its glucuronide.  BPA glucuronide is the major BPA metabolite and has 
little or no estrogenic activity (Volkel et al. 2002).  BPA is conjugated in the liver by an 
isoform of UDP-glucuronosyltransferase namely UGT2B1 (Yokota et al. 1999).  BPA is 
also conjugated to BPA sulfate by phenol sulfotransferases found in the liver (Suiko et al. 
2000; Ye et al. 2005); sulfation of BPA abolishes its estrogenetic activity (Shimizu et al. 
2002).  It is not yet known what proportion of BPA is metabolized to BPA glucuonide 
and BPA sulfate.  BPA achieves maximum circulating concentrations within 12 minutes 
of ingestion, and its elimination half life is 21 hours (Yoo et al. 2000; Yoo et al. 2001).    
BPA is excreted primarily in the urine in adult humans and feces in adult rodents 
(Vandenberg et al. 2007).  Between birth and weaning in rodents, there is typically about 
a 10-fold increase in the rate at which chemicals such as BPA and DES are metabolized 
to inactive conjugates (Fischer and Weissinger 1972; Matsumoto et al. 2002).  However, 
it has also been shown that testosterone reduces the metabolism of BPA in rats (Shibata 
et al. 2002; Takeuchi et al. 2006).  Not all BPA ingested is conjugated by the liver (Zalko 
et al. 2003).  In rodents, conjugated BPA is deconjugated by glucuronidases in the lower 
intestine and colon (Sakamoto et al. 2002).   
At a young age infants may be exposed to both BPA and genistein in high 
quantities.  The purpose of the current study is to determine if exposure to these estrogens 
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individually and concurrently can cause temporary and/or permanent alterations to the 
male reproductive system. 
 
1.3.B. Binding Affinity 
Sir Charles Edward Dodds reported that BPA mimicked the activity of the 
hormone estradiol in 1936 (Dodds and Lawson 1936), making BPA one of the first 
chemicals discovered to possess estrogenic properties.   Dodds also noted that BPA has a 
chemical structure similar to that of the estrogenic drug DES, which was synthesized by 
Dodds a few years after the initial report concerning BPAs estrogenic properties (Dodds 
and Lawson 1936).  Concerns about BPAs estrogenic properties stem from the fact that it 
has similar chemical structure to DES.  It is feared that BPA may be capable of inducing 
reproductive changes similar to those induced in male offspring from mothers treated 
with DES.  These concerns have been substantiated by the finding that the toxicity of 
BPA mainly affects developmental processes and the reproductive system (Miao et al. 
2008). 
The endocrine disrupting potential of BPA is carried out through its ability to bind 
both nuclear ER and  (Krishnan et al. 1993; Soto et al. 1997; Kuiper. et al. 1998) and 
plasma membrane-bound estrogen receptors (Wozniak et al. 2005).  However, BPA 
displays a 10-fold higher binding affinity for ER than ER(Gould et al. 1998; Kuiper et 
al. 1998; Welshons et al. 2006).  BPA is generally classified as a weak estrogen because 
it was found to be about 1,000 - 10,000 times less potent than E2 (Krishnan et al. 1993, 
Kuiper et al. 1998; Sohoni and Sumpter 1998; Welshons et al. 2006).  However, results 
from recent studies have revealed a variety of pathways through which BPA is capable of 
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eliciting cellular responses at very low concentrations (Welshons et al. 2006).  Several 
membrane steroid receptors have been described, including a membrane-bound form of 
ER (mER) that is similar but not identical to the nuclear ER (Powell et al. 2001; 
Watson et al. 2007) and a transmembrane ER called G protein-coupled receptor 30 
(GPR30) (Thomas and Dong 2006).  BPA has been shown to bind to both mER and 
GPR30, and studies have determined that these membrane-bound receptors are capable of 
nongenomic steroid actions (Watson et al. 2005; Thomas and Dong 2006; Watson et al. 
2007).  Information regarding BPA’s ability to bind membrane-bound receptors has led 
some researchers to suggest that BPA may have the same efficacy and potency as  
(Welshons et al. 2003; Watson et al. 2005; Wetherill et al. 2007).  It is known that when 
estrodiol binds ER, the ER regulates the rate of gene transcription through its association 
with coregulators.  However, when BPA binds ER a unique conformation of ER is 
produced altering ER’s interaction with coregulators.   
There is some evidence that BPA binds to the thyroid hormone receptor, acting as 
a thyroid hormone antagonist by preventing the binding of T3.  One study found the 
affinity of BPA for the thyroid hormone receptor several fold lower than its affinity for 
the ERs (Moriyama et al. 2002).  However, other studies have been unable to duplicate 
these results, finding that BPA does not competitively inhibit the binding of labeled T3 to 
the thyroid hormone receptor or induce thyroid hormone-dependent production of growth 
hormone in GH3 cells (Kitamura et al. 2002; Kitamura et al. 2005). 
The antiandrogenic properties of BPA are still disputed.  Using a competitive 
binding assay with labeled dihyroxytestosterone and a yeast reporter assay, antiandogenic 
activity of BPA was detected in the 10-5 to 10-7 M range, making BPA as potent as the 
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antiandrogen flutamide (Sohoni and Sumpter 1998).  However other studies have not 
been able to demonstrate any antagonistic activity (Gaido et al. 2000; Sun et al. 2006; 
Kruger et al. 2008).   
BPA is also capable of binding the aryl hydrocarbon receptor (AhR) (Kruger et al. 
2008), a ligand-dependent transcription factor present in almost every tissue.  AhR is 
thought to be activated through many chemicals with diverse structures and may mediate 
the toxic and/ or biological affects of these chemicals.  Although AhR has been 
implicated in several signal transduction pathways, the effects of BPA binding to AhR 
remain unknown at this time.  AhR can cross-talk with other receptors including ERs and 
the androgen receptor, indicating endocrine-related endpoints may be affected by its 
activation (Pocar et al. 2005). 
It has been found that many estrogenic endocrine disrupting chemicals, including 
BPA, show reduced binding to plasma proteins and thus exhibit an elevated free 
concentration in blood relative to estradiol (Nagel et al. 1997; Nagel et al. 1999). 
Chemicals that can bypass the barriers created by plasma binding proteins (which 
regulate the free fraction of natural or manmade estrogens) have a greater biological 
activity and thus pose a greater hazard than would be predicted if this was not taken into 
account (vom Saal et al. 2005).  
 
   
1.3.C. Reproductive System Effects 
It was discovered in 1936 that bisphenol A could stimulate the growth of the 
rodent uterus, which is an indication of estrogen action (Dodds and Lawson 1936).  
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Although the estrogenic action of BPA has been available for many years, recent 
concerns for a potential relationship between BPA and negative trends in human health 
have spurred research on BPA.  The human health concerns include increases in 
abnormal penile/urethra development in males, early sexual maturation in females, an 
increase in neurobehavioral problems such as attention deficit hyperactivity disorder and 
autism, an increase in childhood and adult obesity and type 2 diabetes, a regional 
decrease in sperm count, and an increase in hormonally mediated cancers, such as 
prostate and breast cancers (vom Saal et al. 2007).  A recent study showed a correlation 
between urinary BPA concentrations and the risk of heart disease, type 2 diabetes, and 
abnormal liver enzymes (Lang et al. 2008).   
Bisphenol A has been tested in male fertility studies in laboratory animals.  Some 
studies have reported no affects on the reproductive function of male offspring following 
maternal exposure (Ashby et al. 1999; Cagen et al. 1999), others have reported that 
exposure to low doses of BPA causes reproductive toxic effects (Nagel et al. 1997; vom 
Saal et al. 1998).  The reported reproductive toxic effects include increases in murine 
prostate gland weight at 6 months of age after exposure in utero to low dose 
concentrations (2 and 20 g/kg/day) (Nagel et al. 1997), and reduced sperm efficiency 
(daily sperm production per gram of testes) in a subset of BPA animals from which 
enlarge prostates had been observed (vom Saal et al. 1998).  Another study has shown 
that doses of BPA between 0.2 and 20 g/kg/day given to rats and mice resulted in a 
significant decrease in daily sperm production and fertility (vom Saal et al. 1998; Al-
Hiyasat et al. 2002; Chitra et al. 2003).  Some researchers have seen transient affects of 
injection of pups with BPA.  Atanassova (Atanassova et al. 2000) treated rats neonatally 
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with a subcutaneous injection of 0.5 mg bisphenol A or vehicle from days 2 – 12, while 
maintained on a standard soy-containing diet.  Testis weight, seminiferous tubule lumen 
formation, the germ cell apoptotic index (apoptotic/viable germ cell nuclear volume), and 
spermatocyte nuclear volume per unit Sertoli cell nuclear volume were used to 
characterize pubertal spermatogenesis.  Treatment with BPA significantly increased 
spermatocytes nuclear volume per unit Sertoli cell and some of the other aspects of 
pubertal spermatogenesis, such as advanced lumen formation.  In general, plasma FSH 
concentrations in the treatment groups changed in parallel to the spermatogenic changes 
(reduced when pubertal spermatogenesis retarded, increased when pubertal 
spermatogenesis advanced).  By day 25, although the changes in FSH concentrations 
largely persisted, all of the stimulatory affects were no longer evident.  In adulthood 
animals treated with BPA had normal or increased testis weights and exhibited 
reasonably normal mating/fertility.  These mixed results do not allow for a clear 
understanding of the effects of BPA treatment. 
Recently regulatory agencies in the United States and the European Union have 
decided that BPA was safe at current levels of human exposure.  Their decision was 
based on a review of all studies conducted using Good Laboratory Practices (GLP).  GLP 
is a federal rule for conducting research on the health affects or safety testing of drugs or 
chemicals submitted by private research companies for regulatory purposes.  The two 
studies that were identified by both the U.S. FDA and the European Food Safety 
Authority as central to the decision to declare BPA as safe at current human exposure 
levels were Tyl el al. (2002; 2008).  Tyl et. al., ( 2002; 2008) determined the no-
observable-adverse-effect level (NOAEL) of BPA by conducting generational studies in 
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both mice and rats.  In the mouse study, these researchers determined that in CD-1-inbred 
mice the NOAEL dose for reproductive toxicity is 50 mg/kg/day, and the NOAEL for 
systemic toxicity is 5 mg/kg/day.   
The U.S. EPA calculated a reference dose (RfD) of 50 g/kg/day for BPA from 
the lowest-observable-adverse-effect level using a safety factor of 1000.  Three safety 
factors of 10-fold each were applied to account for the following: human risk estimated 
from animal studies; variability within human populations; and extrapolation for 
subchronic to chronic exposures (Welshons et al. 2003).  A reference dose is typically 
calculated using the NOAEL, but the reference dose for BPA was calculated using the 
LOAEL because a NOAEL had not been determined and adverse responses were 
detected even at the lowest dose administered (Welshons et al. 2003). 
For many years toxicologists have relied on the principle that “the dose makes the 
poison,” implying that higher doses were expected to cause greater harm.  Thus, effects 
that are not seen at high doses are not expected at low doses.  The threshold model is 
used most often for risk assessment of noncarcinogens (Welshons et al. 2003).  The 
threshold model identifies a “safe” dose by assessing different doses of a chemical until 
the NOAEL is determined.  In contrast to the threshold model, multiple studies have 
found that some hormones exhibit a biphasic dose response for different endpoints 
(Welshons et al. 2003; Vandenberg et al. 2006).  The U-shaped and inverted U-shaped 
dose response curves are considered “nonmonotonic.” U-shaped nonmonotonic dose 
responses curves indicate high responses at low and at high concentrations of exposure, 
whereas inverted U-shaped curves indicate greatest response at intermediate doses 
(Conolly and Lutz 2004). 
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Much controversy exists around the correct NOAEL dose of BPA.  It has been 
speculated by some researchers that BPA exhibits a nonmonotonic dose response curve, 
indicating that high and low doses of BPA have a different affect than medium doses.  
These researchers argue that the dose chosen as the NOAEL by the EPA may be too large 
because doses below the NOAEL were not tested in the study (Willhite et al. 2008). 
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CHAPTER 2: NEONATAL EXPOSURE TO ENDOCRINE DISRUPTORS 
2.1: INTRODUCTION 
 
Genistein is an isoflavone found in high concentrations in soybeans and soy-
protein foods and possesses weak estrogenic activity and thus may alter male 
reproductive development and/or function.  The relative binding affinity of genistein to 
ER has previously been reported as 0.9% of E2 (Shutt and Cox 1972).  Plasma genistein 
concentrations in 4-month-old human infants fed soy infant formula are 2.53 M, a value 
significantly higher than in infants fed either cow’s milk (0.01 M) or human breast milk 
(0.01 M).   
Male reproductive organs including the testis are vulnerable to estrogenic 
compounds.  Neonatal exposure to exogenous steroid hormones such as DES, which is 
well known as a potent synthetic estrogen, reportedly causes marked atrophy of the 
testes, testicular carcinoma, and uterine adenocarcinoma (Arai et al. 1983; Newbold et al. 
1984; 2002; Visser et al. 1998; McLachlan et al. 2001).   
Bisphenol A is an estrogenic endocrine-disrupting monomer used in the 
manufacture of polycarbonate plastic products, including many types of food and 
beverage containers such as baby bottles.  BPA is also used in the manufacture of epoxy 
resins that line metal food and beverage cans such as infant formula cans.  It has been 
known since 1935 that BPA possesses estrogenic properties and has a similar chemical 
structure to DES.  Incomplete polymerization during the manufacture of polycarbonate 
plastics and epoxy resins allows BPA to leach (Brotons et al. 1995; Biles et al. 1997; 
Biles et al. 1997; Carey 2003; Howdeshell et al. 2003).  Concerns over the use of BPA 
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have increased with the detection of BPA in human fetal umbilical cord blood 
(Schonfelder et al. 2002) within the range known to cause increases in prostate gland 
weight in rats and mice (Nagel et al. 1997). 
The discrepancies between the high concentrations of endocrine disruptors that 
are needed to elicit effects in laboratory assays and their low concentrations in the 
environment have lent credence to the belief that risks to human health or wildlife are 
negligible (Safe 1995).  However, a matter that complicates studying the affect of 
endocrine disruptors is the reality that individuals are exposed to multiple endocrine 
disruptors at one time.  The low concentrations of endocrine disruptors in the 
environment and in human tissues have fueled the expectation that synergisms between 
estrogenic chemicals may exist (Kortenkamp and Altenburger 1998).  Although the 
successful demonstration of synergism will help to alleviate some of these beliefs of the 
negligible affect of endocrine disruptors, combinations of estrogenic compounds have not 
been adequately studied.  It is possible that combinations of estrogenic compounds can 
result in effects from synergism to antagonism.  Synergism or antagonism are generally 
identified as outcomes that exceed, or fall short of, responses expected from additive 
interactions of the individual mixture components.  A widely used method of predicting 
additive effects is based on the expectation that the effects of a mixture should be the 
arithmetic sum of the effects of its individual components.  If we look at a human infant 
being fed soy-infant formula we find that in vivo BPA is competing for binding to ERs 
with the endogenous estrogen, E2 and with genistein from soy infant formula.  BPA has a 
relative binding affinity for ER of 0.008% (Blair et al. 2000), whereas Genistein’s 
relative binding affinity is 0.9% (Shutt and Cox 1972).  Accordingly, if equal 
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concentrations were available, the assumed order of binding to the ERs would be E2, 
genistein, and then BPA.  The consequences of concurrent consumption of genistein and 
BPA on the development of the male reproductive tract is not known.    
The goals of the present study were to: 
1. Determine whether neonatal exposure of mouse pups to serum concentrations 
of genistein present in soy-fed infants produces immediate and/or long-term 
male reproductive effects.  It has previously been determined that dosing with 
50 mg/kg genistein in 24% soy infant formula results in a serum concentration 
of genistein equal to that seen in serum of human infants consuming soy 
infant formula (Cimafranca et al. 2009). 
2. Determine whether neonatal exposure of mouse pups to the BPA no-
observable-adverse-effect-level produces immediate and/or long-term male 
reproductive effects. 
3. Identify the affects genistein and BPA would have on the male reproductive 
system.  Genistein was administered at levels that produced physiologically 
relevant serum concentrations.  BPA was administered in three different 
doses. 
I hypothesized that exposure to weakly estrogenic chemicals, such as genistein and BPA, 
will cause male reproductive tract defects. 
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2.2: SPECIFIC AIMS AND HYPOTHESIS 
 
Specific Aim 1: Determine if oral administration of genistein, at levels that produce 
serum concentrations in mouse pups equal to that seen in human infants consuming soy 
infant formula, has an affect on the male reproductive system. 
Many studies on neonatal exposure to genistein have previously been conducted.  
Previous studies have used two main routes of administration: 1. dosing dams, either 
orally or by injection; 2. direct injection of the pups.  These two routes of administration 
do not adequately depict the exposure of human infants to genistein from soy infant 
formula.  Pups from dams that were dosed with genistein are exposed through lactational 
transfer.  Doerge and colleagues documented that genistein transfer through the milk 
(Doerge et al. 2006) is an inefficient way of transferring genistein.  Dosing dams with 
500 ppm genistein resulted in total genistein concentrations ranging from 0.022 – 0.053 
M in the serum of pups.  If we assume a linear increase of serum genistein 
concentrations with an increase in genistein consumption, it is estimated that 23,868 ppm 
– 57,500 ppm genistein would need to be consumed by a dam to result in serum 
concentrations in the pups that mimic human infant exposure from soy infant formula.  
Therefore, it is impossible to dose a dam with high enough levels of genistein to obtain 
physiological serum concentrations in the pups.  Direct injection of the pups with 
genistein bypasses first-pass metabolism.  First-pass metabolism is necessary because the 
liver metabolizes the ingested compound delivering only a small amount to the 
circulatory system.  Therefore, bypassing first-pass metabolism may result in the animal 
being exposed to hyperphysiological concentrations of genistein.  In the present study, 
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animals received an oral dose of genistein that resulted in serum concentrations equal to 
that seen in 4-month-old human infants receiving a diet of 100% soy-protein formula 
(2.53 mol/L) (Cimafranca et al. 2009).  The physiological relevance of the dose of 
genistein and the route of administration makes the current model to study the affects of 
genistein on the male reproductive system a physiological one.  I hypothesized that 
exposure to the weak estrogen genistein, at levels mimicking physiological levels seen in 
human infants consuming a diet of soy infant formula, will cause male reproductive tract 
defects.  The endpoints chosen for study were germ cell proliferation, efferent duct 
epithelial cell height, anogenital distance, daily sperm production, testis weight, and 
reproductive performance of male C57BL/6 mice.   
 
Specific Aim 2: Determine if oral administration of Bisphenol A (BPA) has an affect on 
the male reproductive system. 
Administration of the estrogenic compound BPA is thought to have adverse 
effects on development and reproduction.  Previously the no-observable-adverse-effect-
level (NOAEL) for BPA has been estimated as 50 mg/kg/day, through maternal dosing 
(Tyl et al. 2002; Tyl et al. 2008).  I hypothesized that oral administration of 50 mg/kg/day 
of BPA will cause male reproductive tract defects.  The endpoints chosen for study were 
germ cell proliferation, efferent duct epithelial cell height, anogenital distance, daily 
sperm production, testis weight, and reproductive performance of male C57BL/6 mice.   
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Specific Aim 3: Determine if concurrent neonatal exposure to genistein and the NOAEL 
of BPA has a synergistic affect, thus increasing the perturbations seen on the male 
reproductive system. 
It has recently been observed that a mixture of estrogens can cause estrogenic 
effects in vitro despite the individual components being present below their respective 
NOAELs (Silva et al. 2002).  The ability of mixtures of estrogens, below their respective 
NOAELs, to cause estrogenic effects indicates that they may cause estrogenic effects in 
vivo as well.  I hypothesized that neonatal exposure of male C57BL/6 mice to 
combinations of genistein and BPA at the NOAEL of BPA and below will alter male 
reproductive development.  The endpoints chosen for study were germ cell proliferation, 
efferent duct epithelial cell height, anogenital distance, daily sperm production, testis 
weights, and reproductive performance.  Three different doses of BPA in combination 
with 50 mg/kg genistein were chosen (BPA: 0.5, 5, 50 mg/kg).  The doses of BPA were 
chosen because 50 mg/kg/day is the NOAEL for reproductive/developmental toxicity, 5 
mg/kg is the NOAEL for systemic toxicity, and 0.5 mg/kg is a ten fold lower dose than 
the systemic NOAEL (Tyl et al. 2002; Tyl et al. 2008).  Since the late 1990s, a large 
volume of research has been generated suggesting a possible ‘low’ dose affect for weakly 
estrogenic environmental contaminants, such as BPA.  The National Toxicology Program 
(NTP) defines ‘low’ dose for BPA as ≤ 5 mg/kg bw/day (Melnick et al. 2002).  The 0.5 
mg/kg dose is less than the defined ‘low’ dose and may give different results from what is 
seen at the 50mg/kg and 5 mg/kg dose. 
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2.3: MATERIALS AND METHODS 
 
2.3.A. Mice 
 Breeder C57BL/6 animals were purchased from Harlan.  These animals were bred 
to produce litters.  Animals were housed in ventilated cages with 1/8 inch corn cob 
bedding, with a light: dark cycle of 12h: 12h.  Breeder animals were fed Harlan 8604 
feed.  Dams at day of birth were switched to the phytoestrogen-free 2016 diet from 
Harlan.  Pups remained on the 2016 diet for the remainder of the experiment. 
 
2.3.B. Chemicals 
The vehicle was an emulsion of 24% soy infant formula (Similac Isomil 
Advanced soy formula with iron) with 0.01% corn oil.  Genistein was a kind gift from 
Dr. W. Helferich (Department of Food Sciences and Human Nutrition, University of 
Illinois).  The genistein stock is a suspension and was delivered in vehicle at 25 mg/L of 
emulsion.  Soy infant formula was used as a vehicle for BPA treatment to reduce 
variability when comparing results from the combined dosing of genistein and BPA.  
BPA was purchased from Sigma - Aldrich (St. Louis, MO).  The BPA stock is a 
suspension and was delivered in vehicle at 25 mg/L of emulsion.  The BPA and 
genistein stock was made in three separate concentrations.  The concentrations were 
genistein (25 mg/l) and BPA (25 mg/l), genistein (25 mg/l) and BPA (2.5 mg/l), and 
genistein (25 mg/l) and BPA (0.25 mg/l).  All stocks were prepared once a week in 5 
ml Eppendorf tubes and stored at 4° C.  The DES stock was purchased from Sigma - 
Aldrich.   
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2.3.C. Dosing 
 On the day of birth (postnatal day 1, PND 1), litters were adjusted to eight pups.  Pups 
were dosed once daily from PND 1 – 5.  Each pup was weighed and dosed with vehicle, 
50 mg/kg genistein, 50 mg/kg BPA, 50 mg/kg genistein and 0.5 mg/kg BPA, 50 mg/kg 
genistein and 5 mg/kg BPA, or 50 mg/kg genistein and 50 mg/kg BPA at 2l per gram of 
body weight.  Some pups were dosed with 1ng/g DES in olive oil, at 10l per gram of 
body weight.  Genistein and BPA stock are not soluble and settle quickly; therefore, the 
solutions were vortexed 5-7 seconds immediately before each use.  Eppendorf tubes with 
dosing material were warmed in a water bath in order to enhance the pup’s suckling 
reflex.  The same 20l pipette was used to measure out the appropriate dose for all 
experimental animals.  To administer the treatment the tip was placed in the mouth of the 
pup and the liquid was slowly dispensed to the pup.  Care was taken to ensure the pup 
swallowed all of the suspension, and that some was not displaced from the mouth.   
 
2.3.D. Germ Cell Proliferation 
The detection of proliferating germ cells was performed through the co-immuno-
localization of a nuclear marker of proliferation (Ki67) and a nuclear marker of germ 
cells (germ cell nuclear antigen, GCNA).  Testis samples were collected at PND 5 and 
fixed overnight in neutral buffered formalin.  Fixed testis samples were dehydrated in 
increasing ethanol concentrations, clarified in xylene and embedded in paraffin wax.  
Five-micrometers-thick sections were de-paraffinized in xylene, re-hydrated through 
graded ethanol solutions.  Antigen retrieval was performed by boiling the slides for 10 
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minutes in 0.01 M citrate buffer (pH 6).  Slides were allowed to cool for 20 minutes and 
then rinsed in phosphate buffer saline 0.01 M (PBS; 8.5g/L NaCl, 2.17g/L Na2HPO4-
7H2O, 0.26g/L NaH2PO4-H2O, pH=7.4).  A permeabilization step was also performed.  
Slides were incubated in PBS-Triton X-100 (0.1%) for 20 minutes at room temperature 
and then rinsed in PBS.  The sections were then incubated for 30 minutes in blocking 
buffer (PBS-BSA 3%, tween 0.1%) to block non-specific binding sites for 
immunoglobulins.  The sections were then incubated overnight at 4 °C in a moist 
chamber with monoclonal antibodies to Ki67 (Abcam, Cambridge, MA, USA) diluted 
1:1000 in blocking buffer, and GCNA (a gift from Dr. Enders, University of Kansas 
Medical Center) diluted 1:5 in blocking buffer.  After rinsing for 15 minutes in PBS plus 
Tween 0.1%, the slides were incubated under light protection for 2 h with Tritc goat anti-
rat IgM (Southern Biotech, Birmingham, AL) and Alexa Flour 488 donkey anti-rabbit 
IgG (Invitrogen, Carlsbad, CA, USA) diluted 1: 100 in blocking buffer.  Slides were then 
cover slipped.  Photographs of slides were taken using an Olympus fluorescent 
microscope.  Images were analyzed using the NIH Image J software program.  To 
confirm the specificity of the immunostaining, control-staining procedures were carried 
out by omission of the primary antibody. 
 
2.3.E. Efferent Ductule Epithelial Cell Height 
Cross-sections of efferent ducts were evaluated using the NIH Image J program.  
The height of the efferent duct epithelium was measured using the length tool.  
Measurements of the height were taken at right angles from the base of the cell adjacent 
to the basement membrane to the luminal surface of the cell.  For each animal, at least 25 
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cells were measured, with sampling from a number of different ducts, and calculating the 
mean value.  Efferent duct epithelial height was assessed at PND 5. 
 
2.3.F. Anogenital Distance 
Anogenital distance (AGD) is defined as the distance between the anterior edge of 
the anus and the posterior edge of the genital tubercle.  AGD of male mice was measured 
using a digital micrometer on days 7, 21, 35, and 110.  AGDs were recorded by one 
person to increase precision and to control for operator variation.   
 
2.3.G. Daily Sperm Production 
To determine daily sperm production, testis were removed from adult mice, 
weighed, and then homogenized in 10 ml of homogenization solution (0.05% triton X-
100 in 0.15 M NaCl) for three minutes.  Homogenate solution was mixed with 0.4% 
trypan blue and observed under the microscope.  Sperm numbers were obtained by 
counting using a hemocytometer. 
 
2.3.H. Reproductive Performance 
Eight-five-day old mice were housed with two adult untreated females for 3 wks 
consecutively.  Each week, males were placed with two different females.  Females from 
each breeding pair were observed for 21 days after separation or parturition, whichever 
came first.  The total number of pregnant females for each male was recorded. 
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2.3.I. Statistical Analysis 
 Data are reported as means ± SEM.  The differences between the means of 
vehicle treated group and the means of a treatment group was analyzed using Student’s t-
test.  Means were considered significantly different if P < 0.05. 
 
2.4: RESULTS 
 
2.4.A. Body weight 
 Body weights of animals treated with 50 mg/kg genistein were not significantly 
different at any time point measured (Figures 4 and 5).  Body weights of animals treated 
with 50 mg/kg BPA were significantly different at PND 3 and 5, but not at any adult time 
points measured (Figures 6 and 7).  Body weights of animals treated with 50 mg/kg 
genistein and 0.5 mg/kg BPA (Gen/BPA0.5) were significantly different at PND 2, 4, and 
5, but not at any adult time points measured (Figures 8 and 9).  Body weights of animals 
treated with 50 mg/kg genistein and 5 mg/kg BPA (Gen/BPA5) were significantly 
different at PND 3, 5, 28, and 84 (Figures 10 and 11).  Body weights of animals treated 
with 50 mg/kg genistein and 50 mg/kg BPA (Gen/BPA50) were significantly different 
from vehicle-treated animals only at PND 28 (Figures 12 and 13).  Body weights of 
animals treated with 1 ng/g of DES had significant decreases in body weight compared to 
vehicle-treated animals at all time points measured except PND 1 (Figure 14 and 15).   
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2.4.B. Germ Cell Proliferation 
Germ cell proliferation at PND 5 was also assessed.  Treatment with 50 mg/kg 
genistein did not significantly alter germ cell proliferation (40% ± 3.1% and 48% ± 5.7% 
vehicle - treated and genistein – treated, respectively; Figure 16).  Animals treated with 
50mg/kg BPA had an 18% increase in germ cell proliferation (40% ± 3.1% and 58% ± 
4.3% vehicle - treated and BPA – treated, respectively; p < 0.05; Figure 17).  Treatment 
with Gen/BPA 0.5 caused a 14% increase in germ cell proliferation (40% ± 3.1% and 
54% ± 4.1% vehicle - treated and Gen/BPA0.5 – treated, respectively; p < 0.05; Figure 
18).  Treatment with Gen/BPA5 caused a 10% increase in germ cell proliferation (40% ± 
3.1% and 50% ± 2.2% vehicle - treated and Gen/BPA5 – treated, respectively; p < 0.05; 
Figure 19).  Gen/BPA50 treatment caused a 10% increase in germ cell proliferation (40% 
± 3.1% and 50% ± 2.6% vehicle - treated and Gen/BPA50 – treated, respectively; p < 
0.05; Figure 20).  Treatment with 1ng/g DES caused a 12% decrease in germ cell 
proliferation (40% ± 3.1% and 28% ± 2.7% vehicle - treated and DES – treated, 
respectively; p < 0.05; Figure 21).  
 
2.4.C. Efferent Ductule Epithelial Cell Height 
Epithelial cell height of the efferent ducts was not significantly changed by 
treatment with 50 mg/kg genistein (Figure 22), 50 mg/kg BPA (Figure 23), Gen/BPA5 
(Figure 25), Gen/BPA50 (Figure 26), or 1ng/g DES (Figure 27).  Treatment with 
Gen/BPA0.5 caused a significant increase in effererent duct epithelial cell height 
compared to vehicle-treated animals (Figure 24).  
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2.4.D. Anogenital Distance 
AGD measurements for male animals were performed on PND 7, 21, 35, and 110.  
Males treated with 50 mg/kg genistein had a larger AGD on PND 35 compared to 
vehicle-treated males (Figure 28).  Animals treated with BPA showed a significant 
increase in AGD compared to vehicle-treated males on PND 7, 35, and 110 (Figure 29).  
Males treated with Gen/BPA0.5 showed an increase in AGD at PND 7 compared to 
vehicle-treated males (Figure 30).  Males treated with Gen/BPA5 showed an increase in 
AGD at PND 7 and a decrease in AGD on PND 21 compared to vehicle-treated males 
(Figure 31).  Males treated with Gen/BPA50 showed an increase in AGD compared to 
vehicle-treated males on PND 7 and 35 (Figure 32).  Males treated with DES showed a 
decrease in AGD compared to vehicle-treated males at PND 21 and 110 (Figure 33).  
 
2.4.E. Daily Sperm Production 
Daily sperm production was measured at PND 35 and 110.  No significant change 
in daily sperm production was measured for animals treated with 50 mg/kg genistein 
(PND35: 1.06 ± 0.08 x 106 vs. 0.92 ± 0.09 x 106; PND 110: 2.80 ± 0.14 x 106 vs. 3.06 ± 
0.12 x 106, vehicle vs. genistein, respectively; Figure 34) or Gen/BPA5 (PND35: 1.06 ± 
0.08 x 106 vs. 1.14 ± 0.10 x 106; PND 110: 2.80 ± 0.14 x 106 vs. 2.81 ± 0.19 x 106, 
vehicle vs. Gen/BPA5, respectively; Figure 37).  Males treated with Gen/BPA0.5 (PND 
35: 1.06 ± 0.08 x 106 vs. 1.34 ± 0.15 x 106; PND 110: 2.80 ± 0.14 x 106 vs. 4.10 ± 0.30 x 
106; p < 0.05; vehicle vs. Gen/BPA0.5, respectively; Figure 36) had a significant increase 
in daily sperm production at PND 35.  Males treated with 50 mg/kg bisphenol A (PND35: 
1.06 ± 0.08 x 106 vs. 1.49 ± 0.14 x 106; PND 110: 2.80 ± 0.14 x 106 vs. 3.61 ± 0.28 x 106, 
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vehicle vs. bisphenol A, respectively; p < 0.05; Figure 35), or Gen/BPA50 (PND 35: 1.06 
± 0.08 x 106 vs. 1.43 ± 0.08 x 106; PND 110: 2.80 ± 0.14 x 106 vs. 3.96 ± 0.26 x 106; p < 
0.05; Figure 38) had a significant increase in daily sperm production at both PND 35 and 
110.  Males treated with DES had a significant decrease in daily sperm production at 
PND 35 and 110 (PND35: 1.06 ± 0.08 x 106 vs. 0.74 ± 0.12 x 106; PND 110: 2.80 ± 0.14 
x 106 vs. 2.00 ± 0.24 x 106, vehicle vs. DES, respectively; Figure 39). 
 
2.4.F. Testis Weight 
Testis weight was not altered from treatment with 50 mg/kg/d genistein (Figure 
40), 50 mg/kg/d BPA (Figure 41), Gen/BPA0.5 (Figure 42), Gen/BPA5 (Figure 43), or 
Gen/BPA50 (Figure 44) at either PND 35 or 110.  A significant decrease in testis weight 
was measured for treatment with DES at PND 110 (Figure 45).   
 
2.4.G. Reproductive Performance 
  Reproductive performance was assessed for males from all treatment groups.  
There was no significant difference in reproductive performance between vehicle treated 
males and genistein (Figure 46), BPA (Figure 47), Gen/BPA0.5 (Figure 48), Gen/BPA5 
(Figure 49), Gen/BPA50 (Figure 50), or DES (Figure 51) treated males.  Reproductive 
performance was scored as the number of pregnant females out of the total number bred 
by each male. 
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Figure 4: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in body weight on PND 1 - 5 (n = 15).  Data are shown as mean ± SEM. 
 
 
Figure 5: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in body weight on PND 21 - 110 (n = 15).  Data are shown as mean ± SEM. 
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Figure 6: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A elicited a significant 
change in body weight on PND 3 and 5 when compared to vehicle-treated males indicated by     (n = 
30, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 7: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A did not elicit a 
significant change in body weight on PND 21 - 110 (n = 10).  Data are shown as mean ± SEM. 
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Figure 8: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d bisphenol 
A (Gen/BPA0.5) elicited a significant change in body weight on PND 2, 4, and 5 when compared to 
vehicle-treated males indicated by      (n = 30, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 9: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d of 
bisphenol A (Gen/BPA0.5) did not elicit a significant change in body weight from PND 21 - 110 (n = 
10).  Data are shown as mean ± SEM. 
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Figure 10: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d bisphenol 
A (Gen/BPA5) elicited a significant change in body weight on PND 3 and 5 when compared to 
vehicle-treated males indicated by     (n = 30, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 11: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d of 
bisphenol A (Gen/BPA5) elicited a significant change in body weight on PND 28 and 84 compared to 
vehicle, indicated by     (n = 10, p < 0.05).  Data are shown as mean ± SEM. 
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Figure 12: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d bisphenol 
A (Gen/BPA50) did not elicit a significant change in body weight from PND 1 - 5 when compared to 
vehicle-treated males (n = 35).  Data are shown as mean ± SEM. 
 
 
Figure 13: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d of 
bisphenol A (Gen/BPA50) caused a significant change in body weight on PND 28 as compared to 
vehicle indicated by     (n = 10, p < 0.05).  Data are shown as mean ± SEM. 
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Figure 14: Neonatal treatment of mouse pups with 1ng/g/d DES treatment caused a significant 
decrease in body weight compared to vehicle at all time points measured except for PND 1 of 
treatment indicated by     (n = 20, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 15: Neonatal treatment of mouse pups with 1ng/g/d DES treatment caused a significant 
decrease in body weight compared to vehicle at all time points measured (n = 10, p < 0.05).  Data are 
shown as mean ± SEM. 
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Figure 16: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in germ cell proliferation at PND 5 (n = 10).  Data are shown as mean ± SEM. 
 
 
Figure 17: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A elicited a significant 
increase in germ cell proliferation at PND 5 indicated by  (n = 10, p < 0.05).  Data are shown as 
mean ± SEM. 
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Figure 18: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg of 
bisphenol A (Gen/BPA0.5) caused a significant increase in germ cell proliferation at PND 5 indicated 
by  (n = 8, p < 0.05).  Data are shown as mean ± SEM. 
 
 
 
Figure 19: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d of 
bisphenol A (Gen/BPA5) caused a significant increase in germ cell proliferation at PND 5 indicated 
by  (n = 9, p < 0.05).  Data are shown as mean ± SEM. 
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Figure 20: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d bisphenol 
A (Gen/BPA50) elicited a significant increase in germ cell proliferation at PND 5 indicated by  
(n = 10, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 21: Neonatal treatment of mouse pups with 1ng/g/d DES elicited a significant decrease in 
germ cell proliferation compared to vehicle at PND 5 indicated by  (n = 3; p < 0.05).  Data are 
shown as mean ± SEM. 
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Figure 22: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in efferent ductule epithelial cell height at PND 5 (n = 6).  Data are shown as mean ± SEM. 
 
 
Figure 23: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A did not elicit a 
significant change in efferent ductule epithelial cell height at PND 5 (n = 7).  Data are shown as mean 
± SEM. 
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Figure 24: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d bisphenol 
A (Gen/BPA0.5) elicited a significant increase in efferent ductule epithelial cell height at PND 5 
indicated by  (n = 5, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 25: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d bisphenol 
A (Gen/BPA5) did not elicit a significant change in efferent ductule epithelial cell  height at PND 5 (n 
= 6).  Data are shown as mean ± SEM. 
 
  68
 
Figure 26: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d bisphenol 
A (Gen/BPA50) did not elicit a significant change in efferent ductule epithelial cell  height at PND 5 
(n = 8).  Data are shown as mean ± SEM. 
 
 
Figure 27: Neonatal treatment of mouse pups with 1 ng/kg/d DES did not elicit a significant change 
in efferent ductule epithelial cell height at PND 5 (n = 3).  Data are shown as mean ± SEM. 
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Figure 28: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein caused a significant 
increase in anogenital distance on PND 35 compared to vehicle indicated by (n = 20, p < 0.05).  
Data are shown as mean ± SEM. 
 
 
Figure 29: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A caused a significant 
increase in anogenital distance at PND 7, 35, and 110 compared to vehicle indicated by  (n = 20, 
p < 0.05).  Data are shown as mean ± SEM. 
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Figure 30: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d of 
bisphenol A (Gen/BPA0.5) elicited a significant increase in anogenital distance at PND 7 compared to 
vehicle indicated by  (n = 10, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 31: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d of 
bisphenol A (Gen/BPA5) caused a significant increase in AGD at PND 7 and a significant decrease in 
AGD at PND 21 compared to vehicle indicated by  (n = 10, p < 0.05).  Data are shown as mean ± 
SEM. 
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Figure 32: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d of 
bisphenol A (Gen/BPA50) elicited a significant increase in anogenital distance at PND 7 and 35 
compared to vehicle indicated by  (n = 10, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 33: Neonatal treatment of mouse pups with 1ng/g/d DES treatment caused a significant 
decrease in anogenital distance compared to vehicle at PND 21 and PND 110 indicated by  (n = 
10, p < 0.05).  Data are shown as mean ± SEM. 
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Figure 34: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in daily sperm production (n = 10 for PND 35; n = 18 for PND 110).  Data are shown as mean 
± SEM. 
 
 
Figure 35: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A caused a significant 
increase in daily sperm production at PND 35 and 110 indicated by  (n = 10 for PND 35; n = 12 
for PND 110, p < 0.05).  Data are shown as mean ± SEM. 
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Figure 36: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d of 
bisphenol A (Gen/BPA0.5) caused a significant increase in daily sperm production at PND 110 
indicated by  (n = 10 for PND 35, p = 0.1; n = 10 for PND 110, p < 0.05).  Data are shown as 
mean ± SEM. 
 
 
Figure 37: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d of 
bisphenol A (Gen/BPA5) did not cause a significant increase in daily sperm production at PND 35 
and 110 (n = 10).  Data are shown as mean ± SEM. 
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Figure 38: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d of 
bisphenol A (Gen/BPA50) caused a significant increase in daily sperm production at PND 35 and 110 
indicated by  (n = 10, p < 0.05).  Data are shown as mean ± SEM. 
 
 
Figure 39: Neonatal treatment of mouse pups with 1ng/g/d DES treatment caused a significant 
decrease in daily sperm production compared to vehicle at PND 35 and PND 110 indicated by  
(n = 10, p < 0.05).  Data are shown as mean ± SEM. 
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Figure 40: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in adult testis weight (n = 10 for PND 35; n = 18 for PND 110).  Data are shown as mean ± 
SEM. 
 
 
Figure 41: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A did not elicit a 
significant change in adult testis weight (n = 10 for PND 35, p = 0.06; n = 12 for PND 110).  Data are 
shown as mean ± SEM. 
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Figure 42: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d of 
bisphenol A (Gen/BPA0.5) did not elicit a significant change in adult testis weight (n = 10 for PND 
35; n = 10 for PND 110, p = 0.06).  Data are shown as mean ± SEM. 
 
 
Figure 43: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg of bisphenol 
A (Gen/BPA5) did not elicit a significant change in adult testis weight (n = 10).  Data are shown as 
mean ± SEM. 
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Figure 44: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d of 
bisphenol A (Gen/BPA50) did not elicit a significant change in adult testis weight (n = 10).  Data are 
shown as mean ± SEM. 
 
 
Figure 45: Neonatal treatment of mouse pups with 1ng/g DES treatment caused a significant 
decrease in testis weight compared to vehicle at PND 110 indicated by  (n = 10, p < 0.05).  Data 
are shown as mean ± SEM. 
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Figure 46: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein did not elicit a significant 
change in reproductive performance (n = 11).  Reproductive performance was calculated as the 
number pregnant out of the total number bred. Data are shown as mean ± SEM. 
 
 
Figure 47: Neonatal treatment of mouse pups with 50 mg/kg/d of bisphenol A did not elicit a 
significant change in reproductive performance (n = 10).  Reproductive performance was calculated 
as the number pregnant out of the total number bred. Data are shown as mean ± SEM. 
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Figure 48: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 0.5 mg/kg/d of 
bisphenol A (Gen/BPA0.5) did not elicit a significant change in reproductive performance (n = 11).  
Reproductive performance was calculated as the number pregnant out of the total number bred.  
Data are shown as mean ± SEM. 
 
 
Figure 49: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 5 mg/kg/d of 
bisphenol A (Gen/BPA5) did not elicit a significant change in reproductive performance (n = 12).  
Reproductive performance was calculated as the number pregnant out of the total number bred. 
Data are shown as mean ± SEM. 
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Figure 50: Neonatal treatment of mouse pups with 50 mg/kg/d of genistein and 50 mg/kg/d of 
bisphenol A (Gen/BPA50) did not elicit a significant change in reproductive performance (n = 14).  
Reproductive performance was calculated as the number pregnant out of the total number bred. 
Data are shown as mean ± SEM. 
 
 
Figure 51: Neonatal treatment of mouse pups with 1ng/g of DES did not elicit a significant change in 
reproductive performance (n = 10).  Reproductive performance was calculated as the number 
pregnant out of the total number bred.  Data are shown as mean ± SEM. 
 
 
2.5: DISCUSSION 
 
 The results from this study illustrate that body weight, germ cell proliferation, 
anogenital distance, and daily sperm production were altered with exposure to BPA and 
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combinations of BPA and genistein.  However, treatment with genistein alone did not 
result in significant differences in the reproductive parameters measured when compared 
to vehicle-treated animals except for an increase in anogenital distance at PND 35.  
Treatment with 1ng/g DES resulted in a significant decrease in all parameters measured 
except for efferent ductule epithelial cell height and reproductive performance.  Males 
treated with exogenous estrogens did not have a difference in reproductive performance 
compared to vehicle treated males. 
DES was used as a positive control in these experiments in accordance with the 
National Toxicology Program Peer Review Panel that recommends DES as a positive 
control in studies using estrogenic chemicals such as genistein and BPA (Program 2001).  
DES has previously been shown to have a higher relative binding affinity for ERs than E2 
(399% vs. 100%) (Blair et al. 2000).  A study by Newbold et al. (2001) determined that 
50 mg/kg/day of genistein and 1/ng/g/d DES were capable of increasing uterine weight 
by a similar percentage (202% vs. 190%, genistein vs. DES).  Therefore, a dose of 
1ng/g/day of DES was chosen for use in this study.  This DES dose would have greater 
estrogenic affects than the genistein administered in this study due to route of 
administration.  Positive effects of DES would indicate that C57BL/6 mice are 
susceptible to exogenous estrogen treatment.  Therefore, if results are not seen with any 
other estrogen treatment, then potency of the estrogen, or route of administration may be 
the cause and the negative affects may not be attributed to sensitivity of animal or the 
strain used. 
 Body weights of animals treated with exogenous estrogens were altered primarily 
during the dosing period, except for treatment with DES, which produced lasting 
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changes.  Treatment with genistein did not alter body weights at any time point measured, 
consistent with previous results (Kang et al. 2002; Fielden et al. 2003; Lewis et al. 2003; 
Masutomi et al. 2003; Adachi et al. 2004).  Treatment with DES  reduced body weights at 
all time points measured except the day of birth.  Decreased body weights due to DES 
treatment has been shown previously (Sharpe et al. 1995; Adachi et al. 2004).  The most 
likely cause of decreased body weights is due to a decrease in adipocyte size and number.  
It has previously been shown that administration of exogenous estrogen is capable of 
decreasing adipocyte number (Cooke and Naaz 2004; Cooke and Naaz 2005).  A 
decrease in body weights during the dosing period of DES-treated animals is most likely 
due to the dosing method.  Injection with DES is traumatic to the pups and may impair 
their suckling ability.  Reduced nutrition of DES animals may also be a cause for the 
continued low body weights seen in adulthood. 
There was an increase in germ cell proliferation with 50 mg/kg/d BPA or the 
combination of genistein and BPA in PND 5 testis.  At PND 5 the cells present within the 
seminiferous epithelium are: 1. Sertoli cells; 2. gonocytes; and 3. primitive type A 
spermatogonia (Bellve et al. 1977).  The gonocytes, which are the precursors of the germ 
cell lineage, proliferate until days 14-16 post coitum, depending on the strain of mice 
(Sapsford 1962; Kluin and de Rooij 1981), and then are arrested in the G0/G1 phase of the 
cell cycle.  After birth gonocytes resume their mitotic activity and eventually give rise to 
type A spermatogonia (Sapsford 1962; Kluin and de Rooij 1981).  A study by 
Vergouwen and colleagues (1991) illustrated that gonocyte proliferation begins at birth 
and steadily increases until PND 3.  At PND 1 they showed that the [3H]thymidine 
labeling index was 10.4 ± 3.1% and increased to 24.1 ± 4.1% on PND 3.  They were also 
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able to identify the first primitive type A spermatogonia at PND 3.  The results shown by 
Vergouwen and colleagues (1991) are in accordance with the results shown by Kluin and 
de Rooij (1981) for Cpb-N mice.  However, it was 1-2 days earlier than described by 
Widmaier (1963) for ‘albino-BLUHM’ mice.  A series of studies have identified that the 
fetal/neonatal testis as very sensitive to estrogen exposures, raising the possibility that the 
precursor cells of spermatogonial stem cells might be preferentially targeted by endocrine 
disruptors (Foster 2006; Sharpe 2006).  Li et al. (1997), have shown that rat gonocyte 
proliferation is stimulated in vitro during the early postnatal period.  They showed that E2 
was capable of inducing gonocyte proliferation at a level comparable with that of 
platelet-derived growth factor (PDGF) and that its effect was blocked by the estrogen 
receptor antagonist, ICI 164,384.  It has also been shown that exogenous estrogen 
exposure is capable of up-regulating the expression of PDGF receptors (PDGFR) in 
gonocytes.  Immunohistochemical studies of PDGFR and  proteins revealed that both 
receptors were present in testis before birth and after birth and that they were up 
regulated upon treatment with estrogens in 3-day-old rats, with PDGFR increasing 
dramatically in gonocytes (Thuillier et al. 2003).  Saunders et al. (1998) has shown that 
rat gonocytes express ER the preferential ER isoform of both genistein and bisphenol A.  
Therefore, stimulation of gonocyte proliferation with BPA and the combination of 
genistein and BPA may be through direct targeting of the ER receptor.  Stimulation of 
gonocyte proliferation may also be from up regulation of PDGF receptors.  Treatment 
with genistein alone was incapable of stimulating germ cell proliferation.  The results 
presented here are constant with other results for genistein treatment.  The anti-
proliferative, cytotoxic and differentiation activities of genistein on some tumors, have 
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been demonstrated both in vivo and in vitro (Kanatani et al. 1993; Wei et al. 1993).  
Genistein has also been demonstrated to arrest cell cycle progression at the G2-M stage 
(Matsukawa et al. 1993) and to induce apoptosis in thymocytes (McCabe and Orrenius 
1993) and leukemia cells (Traganos et al. 1992; Bergamaschi et al. 1993).  More recently 
genistein has been shown to inhibit the growth and proliferation of testicular cells, TM3 
(Leydig, mouse), TM4 (Sertoli, mouse), and GC-1 spg (spermatogonia, mouse) (Kumi-
Diaka et al. 1998).  Treatment with DES was capable of decreasing germ cell 
proliferation in this study.  Previous studies have shown that DES decreases the number 
of Sertoli cells (Fielden et al. 2002; Sharpe et al. 2003).  With fewer Sertoli cells to 
nurture the germ cells there may be a higher percentage of germ cells undergoing 
apoptosis and a decrease in germ cell proliferation.   
Efferent ductule epithelial cell height was not altered by treatment with genistein 
or BPA, except for treatment with Gen/BPA0.5.  These results agree with what has 
previously been reported by Fisher et al. (1999).  Fisher et al. found that following 
injection with either 4 mg/kg/day of genistein or 0.5 mg/injection of BPA efferent duct 
epithelial cell height was not affected at PND 10.  However, efferent duct epithelial cell 
height was reduced at PND 18 and/or 25.  This reduction in epithelial cell height was 
only transient, because changes in efferent duct epithelial cell height were not seen in 
animals that were followed through to 35 days and/or adulthood (Fisher et al. 1999).  
These researchers and others have not shown an increase in efferent duct epithelial cell 
height from exogenous estrogen treatment.  It is possible that the increase in efferent 
ductule epithelial cell height seen in animals treated with Gen/BPA0.5 is only transient, 
and caused by the stimulatory effects of the exogenous estrogen.  Therefore, a 
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reevaluation of the efferent duct epithelial cell height of animals in this study should be 
reevaluated at multiple different time points.  Previous studies have shown that neonatal 
treatment of male rats with relatively high doses of DES (10g) causes a range of 
reproductive tract abnormalities, including overgrowth/ distension of the rete testis and 
reduced epithelial cell height in the efferent ducts, epididymis, vas deferens, seminal 
vesicles, and prostate coincident with relative overgrowth of stromal tissue at many of 
these sites (Atanassova et al. 1999; Atanassova et al. 2001; McKinnell et al. 2001; 
Williams et al. 2001a; Williams et al. 2001b).  All of these DES induced changes are 
associated with a loss of AR in the effected tissues as well as in Sertoli cells (McKinnell 
et al. 2001; Williams et al. 2001).  Neonatal treatment with a 100-fold lower dose of DES 
(0.1 g) did not induce these changes (McKinnell et al. 2001; Williams et al. 2001; 
Williams et al. 2001).  The alteration of the androgen: estrogen (low androgen: high 
estrogen) balance may be one of the causes of these abnormalities.  Our data are 
consistent with these results showing that a dose of 1ng DES did not result in a decrease 
of efferent duct epithelial cell height. 
Anogenital distances of males treated with genistein was increased at PND 35 but 
not at any of the other time points measured.  Increases in AGD for animals treated with 
BPA and the combination of Gen/BPA were also seen.  Previous studies have shown that 
genistein does not alter AGD (Kang et al. 2002; Fielden et al. 2003; Lewis et al. 2003; 
Masutomi et al. 2003).  However, these studies have not measured AGD at PND 35.  The 
increase in AGD seen at 35 days may be due to the onset of spermatogenesis.  Anogenital 
distance is an androgen sensitive target.  Intratesticular levels of testosterone must be 
higher than blood levels of testosterone for successful spermatogenesis.  So as 
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spermatogenesis begins there may be a rise in intratesticular levels of testosterone which 
cause a rise in blood levels of testosterone.  The increased testosterone levels may cause a 
transient increase in AGD.  It has been shown that mice treated with BPA have increased 
levels of testosterone (Sharpe et al. 2003).  Sharpe et al, hypothesize that the increased 
levels of testosterone may be due to the induction of supranormal FSH levels 
(Atanassova et al. 2000) leading to increased responsiveness to endogenous LH (Sharpe 
1993).  These increased levels of testosterone may account for the increase in anogenital 
distance seen in animals treated with BPA in the current study.  Similarly, the study by 
Sharpe et al., ( 2003) showed that treatment with DES caused a decrease in testosterone 
concentrations which would indicate a decrease in anogenital distance for these animals.  
The decreases in testosterone concentrations in DES treated animals may be due to a 
decrease in Leydig cell volume per testis (Sharpe et al. 2003).  However, Leydig cell 
volume appears to even out so that in adulthood the numbers are comparable between 
DES and control animals.  Although the Leydig cell volume per testis is comparable DES 
treated animals continue to have decreased testosterone levels (Sharpe et al. 2003).  DES 
treatment in the current study appears to decrease anogenital distance, which may be a 
result of decreased testosterone concentrations because of decreased Leydig cell volume 
per testis. 
Treatment with genistein did not alter daily sperm production, mostlikely due to 
genistein’s inability to cause an increase in germ cell proliferation. Previous studies have 
also seen no change in sperm numbers following genistein treatment (Nagao et al. 2001; 
Shibayama et al. 2001; Kang et al. 2002; Fielden et al. 2003).  Atanassova et al. have 
shown that BPA causes a stimulatory effect on the first wave of spermatogenesis at 
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puberty (Atanassova et al. 2000).  In their study they found that FSH levels mirrored the 
effects seen in spermatogenesis, i.e. higher FSH levels were associated with increased 
spermatogenesis and lower FSH levels were associated with decreased spermatogenesis.  
Results from the current study show an increase of spermatogenesis due to treatment with 
BPA and the combination of Gen/BPA0.5 or Gen/BPA50.  It is possible that the increase 
in spermatogenesis is due to an increase in FSH levels.  Another explanation for the 
increase in daily sperm production may be due to a direct effect of BPA on Sertoli and/ or 
germ cells.  Sertoli cells, spermatogonia, and most spermatocytes express ER at all 
stages of normal pubertal development (Saunders et al. 1997; Saunders et al. 1998; van 
Pelt et al. 1999), and there are several lines of evidence that suggest direct effects of 
neonatal estrogen treatment on Sertoli cells (Sharpe et al. 1998; Atanassova et al. 1999). 
There are also data in the literature for a number of species that demonstrate stimulatory 
effects of estrogens on gonocytes (Li et al. 1997), spermatogonial stem cells (Miura et al. 
1999), and spermatogonia (Kula 1988; Slowikowska-Hilczer and Kula 1994) as well as 
precocious activation of spermatogenesis in the human testis associated with an estrogen-
secreting tumor (Kula et al. 1996).   Wistuba and colleagues recently demonstrated that 
BPA was capable of increasing Sertoli cell numbers (Wistuba et al. 2003).  However, 
they did not see an increase in spermatogenesis (Wistuba et al. 2003).   
Previous research has shown that treatment with DES was capable of reducing 
Sertoli cell number (Fielden et al. 2002; Sharpe et al. 2003).  The Sertoli cell is 
responsible for supporting germ cells throughout spermatogenesis.  Therefore, it would 
seem likely that if there were fewer Sertoli cells in DES treated animals there would also 
be fewer germ cells.  The reduction of both Sertoli and germ cell number is expected to 
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cause a decrease in testis weight and daily sperm production.  Studies by Majdic et al 
(1996; 1997) have demonstrated that in utero exposure to DES alters the expression of 
SF-1 and Cyp17 in Leydig cells of fetal rats, suggesting that DES effects on 
spermatogenesis are at least in part a result of inhibition of steroidogenesis.  Early and 
latent alterations in the expression of genes involved in estrogen signaling (ER), 
steroidogenesis (SF-1, Star, Cyp17, Cyp11a, and SR-B1), lysosomal function (LGP85 
and Psap), and regulation of testicular development (Tr2-11, Inhbc, and Hoxa10) were 
observed in prepubertal and adult mice, even long after the cessation of DES exposure 
(Fielden et al. 2002).  Decreased expression of these genes may contribute, together or in 
part, to the decrease in epididymal sperm count and sperm fertilizing ability as a result of 
decreased testicular synthesis of C19 steroids or suppression of ER signaling in the 
Leydig cells, both of which are essential for fertility (Couse et al. 2001).  The findings in 
this work for DES treatment are consistent with what has been previously reported 
(Sharpe et al. 1995; 2003 Shibayama et al. 2001; Fielden et al. 2002).  The most likely 
cause for the decrease in daily sperm production of males treated with DES is due to a 
decrease in number of Sertoli cells.  To identify the true cause of a decrease in daily 
sperm production the number of Sertoli cells from animals in this experiment should be 
counted.  The Sertoli cell is responsible for nurturing germ cells and aiding them in their 
progression to spermatozoa.  Therefore, any alteration in Sertoli cell numbers/function 
would result in changes in spermatogenic output. 
Testis weight of animals treated with genistein was also not altered.  The majority 
of the cells within the testis are germ cells.  Therefore a change in germ cell number is 
expected to lead to an increase/decrease in testis weight (Atanassova et al. 2000).  
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Therefore, genistein’s inability to cause an increase in germ cell proliferation is 
consistent with no increase in testis weight.  Previous research has also shown that 
genistein does not alter testis weight (Fisher et al. 1999; Atanassova et al. 2000; Nagao et 
al. 2001; Shibayama et al. 2001; Kang et al. 2002; Fielden et al. 2003; Masutomi et al. 
2003; Adachi et al. 2004).  Neonatal treatment with BPA or the combination of genistein 
and BPA showed a trend toward an increase in this study.  However, no significant 
increases in testis weight were seen.  Previous reports have shown that treatment with 
BPA causes a significant increase in testis weight (Fisher et al. 1999; Atanassova et al. 
2000).  Animals treated with DES in this study had a significant decrease in testis weight.  
Neonatal treatment with DES has previously been shown to decrease testis weight 
(Sharpe et al. 1995; 2003; Fisher et al. 1999; Atanassova et al. 2000; Couse et al. 2001; 
Shibayama et al. 2001; Fielden et al. 2002; Adachi et al. 2004), which is in accordance 
with the results seen in this study.   
Treatment with genistein did not alter reproductive performance, defined as the 
number of pregnant females out of the total number of females bred.  Spermatogenesis in 
male mice produces greater numbers of sperm than are needed for maximual fertility. 
Therefore, a large increase in daily sperm production would be needed to see an increase 
in fertility.  Genistein did not alter daily sperm production and therefore had no change in 
fertility.  The fertility results seen for genistein are consistent with previous research 
(Nagao et al. 2001).  Similarly treatment with BPA or the combination of BPA and 
genistein did not alter reproductive performance.  Reproductive performance of males 
exposed to DES in utero has previously been shown to decrease fertility (Fielden et al. 
2002).  Abnormal sperm morphology and motility, lesions in the reproductive tract, 
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abnormal secretions, and inflammation appear to be related to the decreased fertility 
(Newbold and McLachlan 1985).  The results of this study illustrate that DES treatment 
decreases fertility though it was not statistically significant.   
Previous studies have shown that treatment with BPA results in a nonmonotonic 
dose response curve, indicating that high and low doses have similar effects, whereas 
mid-range doses have effects either above or below the high and low doses (Gupta 2000; 
Markey et al. 2001; Akingbemi et al. 2004).  The results from this study indicate that low 
and high doses of BPA in combination with genistein have the greatest affect on daily 
sperm production.  Males treated with the combination of 50 mg/kg genistein and 5 
mg/kg BPA do not have an increase in daily sperm production compared to the vehicle-
treated males (Figure 37).  However, males treated with the combination of 50 mg/kg 
genistein and 0.5 mg/kg BPA or 50 mg/kg genistein and 50 mg/kg BPA showed 
increased daily sperm production compared to vehicle-treated males (Figures 36 and 38).  
These results indicate that BPA has a U-shaped nonmonotonic dose response curve for 
daily sperm production (Figure 52).  A study conducted by Conolly and Lutz (2004) 
sought to identify a mechanistic explanation for nonmonotonic dose response curves.  
They found that nonmonotonic dose response curves can be explained by straightforward 
biochemical processes or postulated on the basis of reasonable biological hypotheses.  
Other mechanisms that they propose are overshooting homeostatic feedback control or 
shifts in immune responses (Conolly and Lutz 2004). 
The current study utilizes a model for dosing exogenous estrogens that has not 
previously been employed.  The current model more closely mimics human infant 
genistein and BPA exposure, and accounts for first pass metabolism.  My data suggest 
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that neonatal exposure to BPA and the combination of genistein and BPA leads to 
changes in germ cell proliferation in the neonate which ultimately lead to increased daily 
sperm production in the adult.  However, the data also demonstrate that exposure to 
genistein does not have effects on neonatal germ cell proliferation and thus does not alter 
the daily sperm production in adulthood.  The data presented also illustrate that C57BL/6 
mice are susceptible to exogenous estrogen treatment, indicating that the negative results 
seen from genistein treatment are not due to the strain of mouse, but rather the inability of 
the treatment to cause estrogenic effects. 
Irrespective of whether the increase in germ cell proliferation and daily sperm 
production caused by neonatal exposure to BPA or genistein and BPA results from their 
estrogenicity, the key question is whether these effects have relevance to humans.  
Animal studies relevance to humans is a complex issue which requires detailed dose-
response studies and measurement of the pharmacokinetics of BPA in serum of male 
mice.  It would be appropriate to consider whether the concentration of exposure of mice 
to BPA bears any relationship to the equivalent concentration of human exposure.  
Currently the concentration of BPA in serum of bottle-fed human infants is not known.  
To more adequately mimic human infant exposure it is necessary to know the serum BPA 
concentrations, and to determine a dose of BPA treatment for mice that mimics these 
human serum concentrations.  
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Figure 52: Treatment with genistein and BPA at three different doses of BPA reveals a 
nonmonotonic dose response curve for daily sperm production.  Males treated with 50 mg/kg 
genistein and 50 mg/kg bisphenol A (Gen/BPA50) have an increase in daily sperm production when 
compared to males treated with 50 mg/kg genistein and 5 mg/kg bisphenol A (Gen/BPA5) at both 
PND 35 and 110.  Males treated with 50 mg/kg genistein and 0.5 mg/kg bisphenol A (Gen/BPA0.5) 
have a significant increase in daily sperm production compared to males treated with Gen/BPA5 at 
PND 110.  Data are shown as mean ± SEM. Significance indicated by a,b,c.  Treatments with the 
same letter are not significantly different.  Treatments with different letters at a particular age 
indicate a significant difference.   
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CHAPTER 3: SUMMARY AND CONCLUSION 
 
In the current study mouse pups were dosed orally with concentrations of 
genistein that produced biologically relevant serum concentrations, BPA at the 
reproductive NOAEL identified by Tyl et al. (2002; 2008), or with a combination of 
genistein and BPA.  These compounds were administered by a method that takes 
advantage of the natural suckling ability of the pup.  The model used in the current study 
more adequately mimics human infant exposure.  Direct administration of the compound 
to the pup allows for first-pass metabolism, which is essential for understanding the 
effects of these compounds on the body. 
 The results from the current study indicate that genistein, at physiological 
concentrations, and BPA at the NOAEL or below, do not adversely affect several key 
endpoints in male reproductive tract development and function.  In fact BPA may have a 
stimulatory affect on male spermatogenesis (Table 2).  It is likely that exposure to these 
two xenoestrogens has not resulted in the decline in sperm numbers that has been seen 
over the latter half of the twentieth century.  The current study also shows that doses of 
BPA below the NOAEL identified by Tyl et al. (2002; 2008) are capable of causing an 
effect when administered in combination with physiological concentrations of genistein.  
However, in agreement with Tyl et al. (2002; 2008) these effects are not necessarily 
adverse.  Investigation of BPA and genistein’s combined effects on other body organs 
needs to be completed.  Results from these studies will paint a complete picture of the 
combined effects of these endocrine disruptors.  Future studies should aim at using 
concentrations of BPA that mimic human infant serum levels.  Results from these studies 
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will be better able to answer the questions regarding the safety of using plastic baby 
bottles.  Animals in this study were only observed till 4 months of age, and it is possible 
that testicular tumors/cancer may become evident at 12 months of age or greater.  
Therefore, longer term studies on these animals may be necessary to identify the full 
effect of these endocrine disruptors.  More mechanistic studies should also be conducted 
to help identify the cause of the effects seen.  Sertoli cell numbers, testosterone, and FSH 
concentrations should also be measured.  Results from the current study indicate that 
consumption of soy infant formula from plastic baby bottles is not detrimental to the 
development of the male reproductive tract.  It is the conclusion of this author based on 
these results, that it is safe for parents to use plastic baby bottles when administering soy 
infant formula. 
 
Table 2: Summary table describing the results from treatment with 50 mg/kg/d Genistein, or 50 
mg/kg/d BPA, or 50 mg/kg/d genistein and 50 mg/kg/d BPA (Gen/BPA50), or 50 mg/kg/d genistein 
and 5 mg/kg/d BPA (Gen/BPA5), or 50 mg/kg/d genistein and 0.5 mg/kg/d BPA (Gen/BPA0.5).  
Arrow indicates an up regulation of the measured parameter.  Dashes indicate no effect of treatment 
on the measured parameter. 
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